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ABSTRACT - Alzheimer’s disease (AD) is an irreversible neurodegenerative disease characterized by a 
progressive decline in cognition and memory, leading to significant impairment in daily activities and ultimately 
death. It is the most common cause of dementia, the prevalence of which increases with age; however, age is not 
the only predisposing factor. The pathology of this cognitive impairing disease is still not completely 
understood, which has limited the development of valid therapeutic options. Recent years have witnessed a wide 
range of novel approaches to combat this disease, so that they greatly increased our understanding of the disease 
and of the unique drug development issues associated with this disease. In this paper, we provide a brief 
overview of the history, the clinical presentation and diagnosis, and we undertake a comprehensive review of the 
various approaches that have been brought to clinical trials in recent years, including immunotherapeutic 
approaches, tau-targeted strategies, neurotransmitter-based therapies, neurotropic and hematopoietic growth 
factors, and antioxidant therapies, trying to highlight the lessons learned from these approaches.  
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
_______________________________________________________________________ 
 
INTRODUCTION 
 
The progressive growth of the elderly population 
associated with constant increase in life expectancy, 
our limited understanding of the underlying 
mechanisms involved in the etiology of the disease, 
and the lack of reliable and effective preventive and 
disease-modifying therapies available, has rendered 
Alzheimer’s disease (AD) one of the great health 
challenges of the 21st century.  AD is an 
irreversible neurological disorder that destroys 
cognitive function including loss of memory, 
judgment, reasoning, and behavioral control (1).  It 
has serious impact on social functioning, disruption 
of quality of life, and impairment of activities of 
daily living.  It is the most common cause of 
dementia that begins slowly and worsens over time 
with a prevalence that increases with age (2). A 
complex set of cellular events, including feedback 
and feedforward responses of astrocytes, microglia, 
and vasculature might be involved in the etiology of 
AD, which has recently been reviewed by Strooper 
and Karran (3). Increased understanding of the 
underlying mechanisms involved in the etiology of 
the disease during past two decades has led to the 
development of a wide range of novel therapeutic 
approaches. In this manuscript, we focus mainly on 
the therapeutic approaches that have entered clinical 
trials. 
 
History 
Age-related dementia has been recognized since 
ancient times.  One of the earliest references to 
dementia occurring with age is attributed to 
Pythagoras, a 7th century BC Greek physician.  
Pythagoras divided the human life cycle into five 
stages commencing at ages 7, 21, 49, 63, and 81 
years-old, describing the last two stages of life as 
the “senium”, a period characterized by a regression 
in mental capacity and a return to the “imbecility of 
the first epoch of infancy” (4). In 500 BC, the 
Greek Judge Solon recognized the impairments on 
decision making process that could be brought upon 
by old age, revised laws regarding inheritances and 
added the provision that “judgment … [be] not  
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impaired by pain, violence, drugs, old age, or the 
persuasion of a woman” in the making of wills (5). 
In the 13th Century, Friar Roger Bacon recognized 
that “age is the home of forgetfulness” and that loss 
of memory and cognitive function was related to a 
disorder of the brain and not the heart, dispelling 
common notions of that time (4). However, he 
further recognized that specific cognitive deficits 
may be attributed to injuries in different brain areas 
(6).  Dementia, as an abnormal process of aging 
was first recognized in 1901 by Dr. Alois 
Alzheimer, after whom Alzheimer’s disease is 
named. At that time, Dr. Alzheimer began treating a 
51-year old woman named Auguste who had 
symptoms of short-term memory loss and 
confusion. Dr. Alzheimer followed her case until 
she died in 1906, after which he studied her brain 
and determined that her problem was not caused by 
normal dementia due to aging, but a larger health 
issue. She was the first confirmed case of 
Alzheimer’s disease.  In 1976, neurologist Dr. 
Robert Katzman, a pioneer in Alzheimer’s research, 
identified Alzheimer’s as the most common form of 
dementia and proposed that it may be a common 
cause of death calling it a “major killer” (7). In 
1993, apolipoprotein E (APOE), which is located on 
chromosome 19, was the first gene found to be 
related to the risk of Alzheimer`s.  Other genes 
were subsequently found to be linked to AD (8) 
identifying possible genetic etiologies for some 
forms of AD. 
 
Epidemiology 
It is estimated that approximately 44 million people 
worldwide are living with Alzheimer's disease. 
However, only 11 million have been officially 
diagnosed with AD. Women are more likely to 
develop Alzheimer's disease than men of the same 
age. Alzheimer's disease is most common in 
Western Europe, followed by North America, and is 
least prevalent in sub-Saharan Africa (9). The 
global cost of AD and dementia was estimated at 
605 billion dollars in 2015. From 2000-2013, AD 
was the 6th leading cause of death in the United 
States (10), and it is expected to be the third leading 
cause of death of elderly after cancer and heart 
disease.  AD is also the only disease in the top ten 
causes of death that cannot be stopped,   
 
 Figure 1. Statistical data for Alzheimer’s disease in United States, based on the data extracted from [10]. 
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cured, or prevented. Among 5.3 million Americans 
with AD, 5.1 million are aged 65 and older. Figure 
1 summarizes the distribution of AD based on age, 
gender, and race. 
 
Etiology 
The etiology of AD is uncertain; however, genetics, 
environmental, and developmental components are 
likely to play a role.  The greatest risk factor for AD 
is advancing age, although genetics has also been 
extensively studied.  Mutations in three genes, 
amyloid precursor protein (APP), presenilin (PS)-1 
and PS-2 (both affecting APP processing and 
production of amyloid-beta peptides), cause early-
onset (<60 years) autosomal dominant AD. Early 
onset-AD, however, accounts for only 1% of AD 
cases (11).  Late-onset AD (>60 years) has most 
often been genetically linked to apolipoprotein 
(Apo) E ɛ4.  Apo E4 has a gene-dose effect on 
increasing the risk and lowering the age of both 
familial and sporadic forms of late-onset AD.  
While Apo E4 is the top gene associated with late 
onset-AD gene, other genes that may modulate the 
risk of late-onset AD include CLU, CR1, PICALM, 
BIN1, SORL1, GAB2, ABCA7, MS4A4/MS4A6E, 
CD2AP, CD33, APHA1, and HLA-DRB1/5.  Other 
risk factors for AD include head trauma, female 
gender, learning disabilities, education level, 
homocysteine levels, socioeconomic status, and 
previous depression (12). Importantly, vascular risk 
factors including diabetes and hyperlipidemia are 
additional risk factors for AD (13, 14).  However, 
age and the Apo E4 allele continue to be the most 
significant risk factors for the development of AD 
along with female sex (15). The greater prevalence 
of AD in women could be attributed to the higher 
life expectancy in women, since the incidence of 
AD in earlier ages is comparable between sexes 
(16).  
 
Pathophysiology of AD 
AD is a progressive neurodegenerative brain 
disorder.  At the cellular level, AD is characterized 
by a progressive loss of cortical neurons most 
notable in the entorhinal cortex, hippocampus and 
posterior cingulate cortex (12). The neuronal 
damage is believed to be related to the deposition of 
abnormal proteins, which are the hallmark 
pathological lesions of AD known as the “plaques”, 
found in the extracellular space, and “tangles”, 
inside the cells. The neurotic plaques characteristics 
of AD include amyloid deposits consisting of 
amorphous aggregates of misfolded amyloid-beta 
(Aβ) protein (29). The “Amyloid Hypothesis” 
assumes a central role for Aβ in the pathogenesis of 
AD and characterizes AD as a “protein misfolding 
disease” which leads to aggregation and toxic 
accumulation of Aβ in the brain (17, 18).  However, 
although accumulation of Aβ has been linked to 
AD; the role of the protein in AD is not entirely 
clear. 
Aβ is produced from a precursor protein known 
as amyloid precursor protein (APP), a highly 
conserved membrane protein mainly expressed 
around the synapse of neuronal tissue (19). APP 
seems to be involved in neuronal plasticity and 
synapse formation (20). It is metabolized via two 
distinct pathways: (i) non-amyloidogenic pathway 
(due to the non-aggregating nature of the products); 
and (ii) amyloidogenic pathway responsible for Aβ 
synthesis.  The non-amyloidogenic metabolic 
pathway is initiated by α-secretase and further 
processed by γ-secretase, which are members of a 
family of proteolytic proteins with a disintegrin and 
metalloprotease domain (ADAM) (21).  The 
amyloidogenic pathway is initiated through 
cleavage of APP by β-secretase (also known as 
beta-site APP cleaving enzyme; BACE1), and again 
processed by γ-secretase (22).  The Aβ fragments 
from the amyloidogenic pathway accumulate to 
form hard, insoluble plaques that are toxic to 
neurons, and can lead to neuronal death.   
Aβ clearance is also affected by the 
Apoliprotein E (ApoE), a lipid binding protein 
involved in the transportation of cholesterol and 
triglycerides to different tissues, including brain 
(23).  Aβ binds to various regions of ApoE, and 
each Aβ-ApoE complex then participates in a 
different metabolic pathway, which includes: (1) 
clearance by the brain blood barrier; (2) degradation 
by amyloid degrading enzyme (ADE); and, (3) 
deposition of Aβ into the cells. ApoE exists in 
different isomers, and each Aβ–ApoE complex is 
believed to have different rates of catabolism. 
Catabolism of Aβ-Apo E4 has been found to be 
specifically reduced with age, leading to reduced 
availability of ApoE in brain, which in turn results in 
accumulation of toxic cholesterol and Aβ oligomers, 
increasing the risk of AD (24), while Apo E2 and 
APO E3 eliminate Aβ by degradation or transport 
(25). This mechanism is illustrated in Figure 2 
(reproduced from (26)).  
J Pharm Pharm Sci (www.cspsCanada.org) 20, 184 - 225, 2017 
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Figure 2. LRP1 mediates efflux of unbound Aβ and Aβ bound to ApoE2, ApoE3 or α2M from the brain parenchyma into 
the blood with the help of ABCB1; ApoE4 inhibits this transport process. Figure reprinted with permission from Tarasoff-
Conway JM, et al. Nat Rev Neurol. 2015;11(8):457-70 [26]. 
 
 
Although abnormal aggregation and deposition 
of Aβ has attracted popular attention in the last 
decade as the primary causative mechanism of AD, 
it has been proposed that a second mechanism 
might play an equally important role in the 
pathophysiology of AD (27) via formation of 
neurofibrillary tangles. These tangles are insoluble 
fibers found within the somatodendritic and axons 
in AD patients (28). Neurofibrillary tangles 
primarily consist of abnormal aggregation of a 
protein called tau. Tau was originally recognized as 
the main microtubule-associated protein in the 
mammalian brain in 1975 (29), and is mostly 
expressed in axons, where it stabilizes the 
microtubules and promotes transportation of 
nutrients and other important molecules.  Axon 
deficits observed in AD have been at least partially 
linked to aberrant hyperphosphorylation of tau, 
which reduces the capability of Tau in stabilizing 
the microtubules (27). In AD, hyperphosphorylated 
tau has been identified as the primary component of 
the neurofibrillary tangles (30, 31). The formation 
of these tangles correlates with the severity of AD 
(32, 33). It has also been shown that ApoE ɛ4 is 
associated with increased tau accumulation (28).  
 
Clinical features of Alzheimer’s Disease 
AD is characterized by a progressive loss of 
J Pharm Pharm Sci (www.cspsCanada.org) 20, 184 - 225, 2017 
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memory and other cognitive functions that over 
time lead to aphasia, apraxia, agnosia, and reduced 
visual perception. Changes in memory and daily 
activity are usually the first changes noted at the 
time of diagnosis, although many patients may also 
display other subtle symptoms of cognitive 
impairment (34, 35).  These include symptoms such 
as forgetting words, difficulty remembering names, 
reduced ability to solve daily problems, and 
geographic disorientation to the extent that an 
Alzheimer’s patient will usually lose his way home 
(36). In later stages, neuropsychiatric symptoms 
appear including depression, agitation and 
hallucinations with gradual and progressive loss of 
self-awareness and insight (36). In early stages a 
patient can care for his/her basic needs and can 
participate in some activities and hobbies. During 
the late stages of the disease, patients lose the 
ability to manage basic activities of daily life, such 
as personal hygiene, toileting, eating, and dressing.  
The duration from the onset of the disease to death 
is approximately 7 years (37). 
 
Diagnosis of AD 
There is no specific test to detect Alzheimer’s 
disease, and the diagnosis is based on clinical 
history obtained from the patient and the patient’s 
family. Assessment of cognitive function by mental 
status examination is a necessary component of AD 
diagnosis.  Patients diagnosed with AD are 
classified based on criteria as probable AD or 
possible AD with and without evidence of AD 
pathophysiologic processes. Laboratory and 
neuroimaging studies are used as an adjunct to the 
clinical criteria for AD.  Brain imaging studies such 
as MRI and PET scans, can support the diagnosis of 
AD, only if there is evidence of abnormality such as 
brain atrophy or decreased fluorodeoxyglucose 
(FDG) uptake on PET, as biomarkers for 
neurodegeneration and evidence of the downstream 
effects of AD pathophysiologic processes (Figure 
3; (38)). Positive PET amyloid imaging can also 
contribute to the clinical diagnosis of AD. 
Laboratory studies such as low CSF AB42, also a 
biomarker of brain amyloid-beta protein deposition 
and elevated CSF tau (total and phosphorylated), 
are also evidence of AD pathophysiologic 
processes.  
Currently, AD can only be diagnosed based on 
symptoms. However, the pathophysiologic 
processes of AD begin long before the symptomatic 
phases appear.  Therefore, literature suggest that 
AD should be divided into three phases: (a) Pre-
clinical AD: Very early signs and symptoms: 
patient has more memory problems than normal, 
but symptoms are not severe, and their ability to 
participate in normal daily activity is not impaired 
(39); (b) Mild cognitive impairment (MCI): mild 
changes in thinking and memory, but daily activity 
is not compromised. Patients are often diagnosed in 
this stage (40); and (c) Clinical AD: thought, 
behavior and memory symptoms that impair daily 
activity and life (41). Use of the aforementioned 
biomarkers and other biomarkers that measure 
neuronal integrity, amyloid plaques and 
neurofibrillary tangles (which are present before 
cognitive deficits) will help to identify AD patients 
prior to symptoms and pave the way for early 
treatment. 
 
Therapeutic Approaches 
The non-pharmacological approaches to prevent 
AD include relaxing activities, such as listening to 
music or cooking that are speculated to improve the 
neural efficacy of cognitive processing and 
emotional and behavioral functioning (42). On the 
other hand, the therapeutic agents currently in the 
market do not impact the progression of AD and are 
only expected to alter the cognitive symptoms, 
which appear in later stages of AD. In the next 
sections we will review the most recent attempts in 
search for more effective therapeutic approaches.  
 
Beta Amyloid Therapy 
Active immunotherapy 
Active immunization (vaccination) against Aβ is 
one of the therapeutic approaches for AD that has 
been pursued in the past two decades. Active 
immunization against Aβ1-42 (the predominant 
form of beta-amyloid found in the senile plaques of 
AD) in mouse models of AD has been successful in 
prevention and reversal of amyloid plaques, 
neurotic dystrophy, synaptic loss, and gliosis with 
correlating improvement of impaired behavioral 
performance. Active immunization was first 
attempted in humans in 2000 with the first-
generation vaccine AN-1792, a synthetic full-length 
Aβ1-42 peptide linked to QS-21, a carrier made of 
inactivated diphtheria toxin for stimulation of 
immune system. This first attempt caused an aseptic 
meningoencephalitis observed in 6% (18/300) of 
vaccinated patients (43).  
J Pharm Pharm Sci (www.cspsCanada.org) 20, 184 - 225, 2017 
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 Figure 3. Neuroimaging studies: a, compared with the normal brain of a healthy person on the right, the brain of an 
Alzheimer’s disease patient exhibits marked atrophy as evidenced by the increased prominence of the sulci and gyri on the 
surface of the AD brain, particularly in the temporal and frontal lobes; b, Sagittal positron emission tomography (PET) 
images of a normal and AD brain show glucose uptake in a normal control subject on the left (red and yellow indicate high 
levels of glucose uptake), while the brain of Alzheimer’s patient on the right exhibits large decreases in energy metabolism 
in the frontal cortex (top of PET image) and temporal lobes (sides of PET image). Reprinted from [38]. 
 
 
This was later attributed to a T-cell mediated 
response to Aβ residues 15-42 and the phase II trial, 
which began in AD patients in late 2001 was 
terminated just a few months into the trial in early 
2002 (NCT00021723).  Further supporting early 
termination was data showing that the 
immunological response to the vaccine was weak, 
with only 20% of patients producing a significant 
antibody response primarily against the N-terminus.  
However, a later 4.6 year follow-up revealed that 
vaccinated AD patients reported a functional benefit 
in the years after vaccination and postmortem 
pathology examination of vaccinated patient brains 
found marked clearance of insoluble amyloid 
J Pharm Pharm Sci (www.cspsCanada.org) 20, 184 - 225, 2017 
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plaques. Phospho-tau analysis showed a reduction 
of aggregated tau in neuronal processes (44). These 
findings encouraged further development of other 
candidates that would avoid the above problems for 
active vaccination. 
Second-generation vaccines have been designed 
using shorter Aβ peptide segments directed at the 
N-terminal end of the Aβ protein, which was 
believed to contain a B-cell epitope while avoiding 
T-cell activation from Aβ residues 15-42.  Many of 
these second generation vaccines including ACC-
001, Affitope AD-02, V-950, and ACI-24 have 
undergone phase II trials as detailed below. Others, 
including MER5101, UB-311, Lu AF20513, and 
CAD 106 are in various stages of preclinical, phase 
I, II, and phase II/III testing respectively as detailed 
in Table 1. Each of these compounds are associated 
with unique drug development strategies relayed 
below.  
ACC-001, also known as vanutide cridificar, 
was designed as a conjugate of multiple short Aβ 
fragments consisting of amino acids 1-7 again 
linked to QS-21 (similar to the first generation 
vaccine AN-1792) for immune stimulation.  
Vanutide was tested in patients with mild-to-
moderate AD in multiple phase II trials in the mid 
to late 2000s (NCT01284387, NCT00955409, 
NCT00752232, NCT00498602, NCT01227564, 
NCT00479557, and NCT00959192).  In the trials, 
more than 90 percent of participants in the active 
groups responded to the vaccine by making 
antibodies, which was an improvement over AN-
1792 in which only 20% of participants responded 
by making antibodies.  However, the molecule was 
still plagued by side effects including amyloid-
related imaging abnormalities with vasogenic 
edema (ARIA-E), indicative of potential new 
microhemorrhages, occurring in two (0.8%) 
patients. Despite the occurrence of ARIA-E, which 
would prove to be consistently associated with most 
if not all of the active vaccines, the molecule was 
concluded to have an acceptable safety profile.  
Further exploratory cognitive evaluations, 
volumetric brain MRI, and CSF biomarkers, 
however, did not show differences between 
treatment groups and placebo although some trends 
were seen including less brain amyloid 
accumulation in vaccinated patients as assessed by 
PET imaging and slight reductions in CSF 
phosphorylated tau (45, 46). The development of 
this vaccine is not being further pursued and long 
term extension studies were terminated in 2013 
(NCT0096053, NCT01238991).  
Affitope AD-02, directed against a slightly 
shorter Aβ peptide sequence fragment, Aβ1-6, was 
derived from a proprietary method termed 
AFFITOPE-technology that produces “non-self” 
proteins and uses aluminum hydroxide as an 
immunological adjuvant believed to be able to 
avoid the adverse effects noted with the other active 
vaccines. This vaccine reached human trials in late 
2000s (47, 48) with phase Ia/Ib studies showing 
favorable safety and tolerability even after 2 years 
despite some concerns with ARIA-E 
(NCT00633841, NCT01093664, and 
NCT00711321).  A phase II trial of AD-02 plus an 
undisclosed immunomodulator was conducted from 
2010-2013 and compared AD-02 to placebo and to 
the immunomodulator itself (NCT01117818) in 
patients with AD.  The trials showed favorable 
safety and tolerability but primary and secondary 
outcome measures were not met in the AD-02 
group and a subsequent phase II study and 
observational follow-up study was terminated 
(NCT02008513, NCT01357629). Surprisingly, 
however, the company announced in a news release 
benefit in the placebo group that received the 
immunomodulator by itself and has renamed this 
immunomodulator AD-04 and is pursuing 
development of this agent. 
V-950 is an Aβ amino terminal peptide 
formulated on an aluminum-containing adjuvant 
along with Iscomatrix™ an improved saponin 
adjuvant with antigen delivery and presentation 
properties as well as immunomodulatory 
capabilities (49). Iscomatrix™ was shown to be 
able to rapidly traffic antigens into the cytosol of 
multiple dendritic cell subsets, induce the induction 
of various cytokines and chemokines, and link 
innate and adaptive immune responses in vivo in a 
toll-like receptor-independent but MyD99-
dependent manner to provide enhanced and 
accelerated immune responses including a response 
from a range of subclasses of antibodies as well as 
CD4+ and CD8+ T-cells (50). A phase I, double-
blind, randomized, placebo-controlled, dose 
escalating study to evaluate the safety, tolerability, 
and immunogenicity of the compound started 
enrolling 86 patients in 2007 with a planned study 
completion date of January 2012 (NCT00464334). 
The authors were unable to find any reports on the 
results for this trial. 
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ACI-24 is a liposome vaccine based on the 
truncated Aβ1-15 sequence that grew out of work 
with tetrapalmitoylated preparations of N-terminal 
Aβ fragments which showed that these preparations 
rapidly stimulated anti-Aβ antibodies that could 
dissolve amyloid fibers in vitro and in vivo.  The 
vaccine consists of an array of Aβ1-15 sequences 
that are sandwiched between palmitoylated lysines 
at either end and are anchored onto the surface of 
the liposomes so that the peptides adopt an 
aggregated β-sheet structure, forming a 
conformational epitope (51). A Phase I/II double-
blind, randomized, placebo-controlled, adaptive 
design study of the safety, tolerability, 
immunogenicity and efficacy of ACI-24 was 
initiated in 2009 and enrolled 198 AD patients at 
five sites in Finland, Sweden, and Denmark 
(EUCTR2008-006257-40-FI).  Patients were treated 
for one year and followed for two or more years. 
No results have been announced, although the 
company has recently launched a phase I trial of 
ACI-24 in Downs Syndrome patient suggesting an 
acceptable safety and tolerability profile of ACI-24 
(NCT02738450). 
MER5101 is a novel conjugate of Aβ1-15 also 
conjugated to diphtheria toxoid (DT), and 
formulated in a nanoparticular emulsion-based 
adjuvant. It has currently only been evaluated in 
animal models but the evidence in these models 
suggest potential for development. High IgG1 and 
IgG2b antibody responses have been observed in 
animal models, suggesting a Th2-biased response.  
A strong proliferative response was observed when 
splenocytes were re-stimulated with the Aβ1-15:DT 
conjugate, whereas proliferation was absent after 
re-stimulation with Aβ1-15 or Aβ1-40/42 peptides, 
indicating a cellular immune response against DT 
while avoiding an Aβ-specific T-cell response. 
Moreover, significant reductions in cerebral Aβ 
plaque burden, accompanied by attenuated 
microglial activation and increased synaptic 
density, and improvement in cognitive deficits in 
contextual fear conditioning and the Morris water 
maze were observed. It is not known whether it will 
move forward into human trials (52). 
LuAF20513 is an engineered protein in which 
Aβ1–12 is repeated three times, interspersing each 
with a stretch of the P30 and P2 Th epitopes from 
the tetanus toxin conventional vaccine. As most 
adults have memory T cells that recognize the toxin 
from prior tetanus inoculation the tetanus toxin 
epitopes are believed to stimulate a T helper cell 
response that induces B cells to make antibodies to 
Aβ. This approach addresses the challenges seen 
with prior Alzheimer’s vaccines which have been 
unable to produce successful antibody responses in 
the immune systems of elderly people whose pool 
of naïve T cells who can take on a new antigen is 
low. Patients who carry pre-existing memory T 
helper cells that recognize tetanus epitopes are 
expected to be able to mount a strong response to 
this recombinant epitope vaccine. In animal models, 
Lu AF20513 was found to induce robust "non-self" 
T-cell responses and induce production of anti-Aβ 
antibodies (53). This vaccine is currently recruiting 
for phase I clinical trials in an open-label, dose-
escalation study to assess its safety, tolerability and 
immunogenicity expected to be completed in 2017 
(NCT02388152).   
The vaccine, UB-311, is an equimolar mixture 
of 2 synthetic peptides coupled through an 
oligonucleotide spacer to Aβ1-14. In animals, UB-
311 produced better antibody responses than did 
Aβ1-14 or Aβ1-28 alone or Aβ1-14 coupled to 
keyhole limpet hemocyanin, a very large, 
immunogenic carrier molecule and also decreased 
the amount of Aβ deposited in brain with 
improvement in learning and short-term memory in 
AD animal models.  In a phase I trial and 
observational extension phase trialconducted in 
YEAR, 19 Taiwanese AD patients showed 
cognitive improvement on various measures with an 
acceptable safety and tolerability profile (54). UB-
311 is now in a phase IIa randomized, double-blind, 
placebo-controlled trials designed as a 3-arm 
parallel-group, multicenter study to evaluate its 
safety, tolerability, immunogenicity, and efficacy 
starting October 2015 with an expected completion 
date of December 2017 (NCT02551809).  
CAD106 combines multiple copies of Aβ1-6 
coupled to a Qβ virus-like particle.  A phase I trial 
in 58 Swedish patients in 2008 (NCT00411580) 
concluded that the vaccine was able to induce 
appropriate Aβ IgG titers and was generally safe 
and well-tolerated with no reports of 
meningoencephalitis (55). CAD106 has since been 
tested in five multicenter phase II trials 
(NCT01097096, NCT00956410, NCT00795418, 
NCT01023685, NCT00733863) in the United States 
and Europe including a 90-week trial, and two 66-
week extension trials exploring intramuscular and 
subcutaneous injections and additional doses of 
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vaccine and adjuvants with different longer-
injection/booster-shot regimens (56). In a unique 
study design compared to the design of prior active 
vaccines, a phase II/III trial began in November 
2015 and is expected to enroll 1,340 homozygous 
ApoE4 carriers who are cognitively normal to a 5-
year treatment period with an expected completion 
date in 2023 and will measure the ability to delay 
diagnosis to MCI or AD dementia (NCT02565511). 
Besides progressive modifications in the structure 
and activity of AD molecules, a similar trend 
towards study designs that target AD at earlier and 
earlier stages will also be seen in the development 
of other therapeutic approaches as well. 
 
Passive immunotherapy 
Passive immunization is currently the most widely 
developed approach in clinical trials, and numerous 
approaches have completed initial stages and are in 
phase III clinical trials. The passive 
immunotherapeutic agents are summarized in Table 
2. 
Bapineuzumab was the first antibody to reach 
advanced stages of clinical development.  
Bapineuzumab is a humanized murine monoclonal 
antibody 3D6, directed against the N-terminal 
region of Aβ1-6.  Bapineuzumab binds to 
aggregated Aβ and to a lesser extent soluble Aβ 
with nanomolar affinity, activating microglial 
phagocytosis and promoting plaque clearance in 
animal models. Bapineuzumab was tested in a 12-
month phase I study with 80 patients 
(NCT00397891) completed in 2007 and an 18-
month phase II study with 234 patients 
(NCT00112073) completed in 2009.  In these initial 
safety studies, 3/10 patients on the highest dose in 
the phase I study and 12 patients in the phase II 
study suffered amyloid-related imaging 
abnormalities indicative of potential new 
microhemorrhages, similar to that seen with active 
immunization (57, 58). Again, despite the results of 
the phase II study, bapineuzumab was deemed to be 
relatively safe and well tolerated as half of the 
ARIA-E cases were asymptomatic, and half 
suffered only transient symptoms with just one 
patient requiring steroid treatment (58). Although 
no significant difference was seen between 
treatment groups and placebo in the pre-specified 
secondary outcome measures of cognition and 
function in the phase II study, post-hoc exploratory 
efficacy analyses hinted at a treatment response in 
Apoε4 non-carriers and some biomarkers did show 
trends towards improvement, including a trend 
towards reduction of CSF P-tau and reduction in 
cortical fibrillar Aβ as assessed by serial amyloid 
PET (58-60). 
Two 18-month phase III trials (NCT00574132, 
NCT00575055) enrolling a total of 2,452 patients 
who were Apoε4 carriers and non-carriers 
respectively, were then completed in 2013.  Both 
trials failed to show a treatment effect on cognitive 
or functional primary outcomes or rate of brain 
volume loss (61). Reductions were seen in CSF p-
tau and amyloid binding as measured by PET was 
not increased from baseline, but this was seen in 
APOε4 allele carriers only and not in non-carriers.  
Furthermore, while treatment seemed to prevent 
increases in plaque buildup, there was no reduction 
of amyloid binding, indicating that while plague 
aggregation may have been prevented, clearance of 
plaque may not have been stimulated.  Additionally, 
ARIA-E was found to occur with increased 
bapineuzumab dose and Apoε4 allele number, 
believed to be in part due to increase Aβ load, 
including vascular Aβ load, in those with increased 
ApoE4 allele number, which ultimately led to 
discontinuation of the highest 2 mg/kg dose. Two 
other phase III trials were terminated on August 6, 
2012 because of this lack of clinical benefit, though 
not necessarily because of any new safety concerns 
(NCT00667810, NCT00676143).  Failure of 
bapineuzumab to achieve clinical benefit has been 
attributed to the dose-limiting ARIA-E adverse 
effect as well as to late-stage treatment (62). 
Solanezumab was the second monoclonal 
antibody to enter advanced clinical development. 
Solanezumab is targeted against Aβ 16–24 and 
unlike bapineuzumab binds with picomolar affinity 
only to the monomeric, soluble, toxic species of Aβ. 
Solanezumab binds soluble Aβ in both the 
periphery and the brain thereby driving the 
equilibrium toward the soluble form, putatively 
resulting in resolution of Aβ plaques (63). 
Solanezumab may also have reduced frequency of 
adverse effects such as ARIA compared to 
bapineuzumab as evidenced even from the very first 
human trial in which no MRI evidence of 
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Table 1 – A summary of the clinical trials based on active immunotherapy approaches (https://clinicaltrials.gov) 
Drug name Clinical trial number & Phase 
Start & End 
date 
Trial 
population Outcome Special notes 
AN-1792 
(first 
generation 
vaccine) 
NCT00021723 
Phase II 
2001 - 2002 300 Functional benefit and marked 
clearance of insoluble amyloid 
plaques with reduction of 
aggregated tau in neuronal 
processes. 
Made of inactivated diphtheria toxin for 
immune stimulation that caused aseptic 
meningoencephalitis observed in 6% 
(18/300) of vaccinated patients. 
ACC-001 or 
vanutide 
cridificar 
(second 
generation) 
Phase II 
clinical trials: 
NCT01284387 
NCT00955409 
NCT00752232 
NCT00498602 
NCT01227564 
NCT00479557 
NCT00959192 
 
 
2011 - 2014 
2009 - 2013 
2008 - 2012 
2007 - 2013 
2011 - 2014 
2007 - 2013 
2009 - 2013 
 
 
126 
50 
40 
160 
63 
86 
32 
Exploratory cognitive 
evaluations, volumetric brain 
MRI, and CSF biomarkers did 
not show differences between 
treatment groups and placebo. 
Used in combination with an adjuvant 
immunostimulatory agent (QS-21). 
Affitope AD-
02 (second 
generation) 
NCT01117818 –   
       phase 2 
NCT00633841 –  
     phase 1 
NCT01093664 – 
      phase 1 
NCT00711321 – 
      phase 1b 
NCT02008513 –  
     phase 2 
NCT01357629 –  
       follow-up 
2010 - 2013 
 
2008 - 2009 
 
2009 - 2010 
 
2008 - 2010 
 
2013 - 2014 
 
2011 - 2013 
335 
 
24 
 
20 
 
23 
 
194 
 
11 
The trials showed favorable 
safety and tolerability but 
primary and secondary outcome 
measures were not met in the 
AD-02 group and a subsequent. 
Uses aluminum hydroxide as an 
immunological adjuvant. 
V-950 (second 
generation) 
NCT00464334 
phase I 
 
2007 - 2012 86 No results have been reported 
for this trial. 
An Aβ amino terminal peptide formulated 
on an aluminum-containing adjuvant with 
Iscomatrix™ an improved saponin adjuvant 
with antigen delivery and presentation 
properties as well as immunomodulatory 
capabilities. 
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Table 1 Continued… 
 
ACI -24 
(second 
generation) 
EUCTR2008-
006257-40-FI, 
Phase I/II 
 
NCT02738450 
 
 
2009 
 
2016 - 2016 
 
 
198 
 
24 
No results have been announced, 
although the company has 
recently launched a phase I trial 
of ACI-24 in Downs Syndrome 
patient suggesting an acceptable 
safety and tolerability profile of 
ACI-24. 
 
MER5101 
(second 
generation) 
    Conjugated to diphtheria toxoid (DT), and 
formulated in a nanoparticulate emulsion-
based adjuvant 
LuAF20513 
(second 
generation) 
NCT02388152 
Phase I 
 
 
Currently 
recruiting 
(expected to be 
completed in 
2017) 
35 Ongoing 
 
 
Is an engineered protein in which Aβ1–12 is 
repeated three times, interspersing each with 
a stretch of the P30 and P2 Th epitopes from 
the tetanus toxin conventional vaccine. 
UB-311 
(second 
generation) 
NCT00965588-   
Phase I 
NCT01189084- 
Patients who 
previously received 
UB311 
NCT02551809- 
phase II 
 
2009 - 2011 
 
2010 - 2011 
 
 
2015 - 2017 
 
19 
 
14 
 
 
45 
 
 
 
 
                    
To Evaluate Safety, Tolerability and 
Immunogenicity of Vaccine (UB 311) in 
Subjects With Alzheimer's Disease 
CAD106 
(second 
generations) 
NCT00411580-  
      Phase I 
NCT01097096- 
     Phase II 
NCT00956410- 
     Phase II 
NCT00795418- 
     Phase II 
NCT01023685- 
    Phase II 
NCT00733863- 
     Phase II 
NCT02565511- 
     phase II/III 
 
2005 - 2008 
 
2010 - 2012 
 
2009 - 2011 
 
2008 - 2010 
 
2009 - 2012 
 
2008 - 2010 
 
2015 - 2023 
 
58 
 
177 
 
21 
 
31 
 
24 
 
27 
 
1340 
Concluded that the vaccine was 
able to induce appropriate Aβ IgG 
titers and was generally safe and 
well-tolerated with no reports of 
meningoencephalitis. 
Phase III: ongoing 
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inflammation, vasogenic edema, or 
microhemorrhage was observed in the first 19 
patients administered a single dose of solanezumab. 
Later phase II single dose studies (NCT00329082, 
NCT00749216) completed in 2008 and 2009 (64, 
65) and an additional phase II, randomized, double-
blind, placebo-controlled trial evaluating patients 
exposed to repeated doses completed in 2012 
(NCT01148498), confirmed the antibody's safety 
and tolerability.  This later phase II trial showed no 
benefits in secondary clinical outcome measures 
and CSF and MRI biomarkers at the end of the 12-
week treatment period (66); however, it showed 
dose-dependent increases in unbound CSF Aβ1-42 
suggesting that solanezumab may shift Aβ 
equilibria and mobilize Aβ1-42 from amyloid 
plaques.  
Phase III trials were initiated in 2009 
[EXPEDITION1 (NCT00905372), EXPEDITION2 
(NCT00904683)] enrolling 2040 AD patients from 
16 countries with mild to moderate AD. When all 
patients were considered, solanezumab failed to 
show benefit in the primary clinical outcome 
measure.  However, when only patients with mild 
disease were analyzed in a pre-planned subgroup 
analysis, improvements in multiple cognitive and 
functional scales including the 14-item Alzheimer’s 
Disease Assessment Scale (ADAS-Cog14) and the 
Alzheimer's Disease Cooperative Study-Activities 
of Daily Living scale (ADCS-ADL) were seen, 
suggesting that positive therapeutic effects were 
possible if treatment was given at an early stage of 
AD (67). Plasma/cerebrospinal fluid biomarker 
findings also indicated target engagement by 
solanezumab and the incidence of ARIA with 
edema or hemorrhage was not significantly 
different from placebo (67, 68). 
Based on these findings, an additional phase III 
trial [EXPEDITION3 NCT01900665] was initiated 
in July 2013 and has finished target enrollment of 
2100 patients with mild Alzheimer’s disease. 
ADAS-Cog14 and the ADCS-ADL scale are the co-
primary outcome measures in this trial with a 
primary completion date expected in October 2016 
and a study completion date expected in October 
2018 (NCT01900665).  Three other phase III trials 
in specific subset populations have also recently 
been initiated including a 48-month trial in patients 
with dominantly inherited AD initiated in 2012 with 
an expected completion date in 2019 that has 
finished actively recruiting (NCT01760005), a 38-
month trial in patients with normal cognitive 
function who are deemed at risk for AD by 
florbetapir PET brain imaging initiated in 2014 that 
is still actively recruiting (NCT02008357), and a 
24-month trial in patients with prodromal AD or 
mild cognitive impairment initiated in June of 2016 
(NCT02760602).   Of note, in all these ongoing 
phase III trials, positivity on PET amyloid imaging 
is an inclusion criterion, as a common finding in 
both trials with both bapineuzumab and 
solanezumab was that a quarter of patients with 
mild Alzheimer’s tested negative by means of PET 
amyloid imaging indicating that a quarter of the 
patients likely did not have Alzheimer’s disease.  
As such, using positive pet amyloid imaging as an 
inclusion criterion will greatly increase the potential 
to show efficacy. 
Gantenerumab is another monoclonal antibody 
being evaluated in AD.  It is a fully human IgG1 
antibody that preferentially binds to aggregated Ab 
in the brain and vasculature with subnanomolar 
affinity and does not alter plasma Aβ. 
Gantenerumab is a conformational antibody that 
possesses two binding sites, one in the N-terminus 
region and another in mid-domain of the Aβ 
peptide, believed to act centrally to disassemble and 
degrade amyloid plaques by recruiting microglia 
and activating phagocytosis (69). Indeed, much 
initial excitement accompanied the very first in 
human studies of gantenerumab as treatment 
resulted in a dose-dependent reduction in brain 
amyloid level, as assessed by percent change in the 
ratio of regional carbon 11-labeled Pittsburgh 
Compound B retention measured by PET. Safety 
wise, four Phase 1 trials (NCT00531804, 
NCT01656525, NCT02133937, NCT01636531) 
conducted internationally in a total of 308 patients 
suggested that gantenerumab was generally safe and 
well-tolerated, although ARIA was observed (70).  
Phase II/III trials of gantenerumab were 
initiated in July 2010 and enrolled 799 patients 
(SCarlet RoAD NCT01224106) and was the first 
large trial to utilize new diagnostic criteria by the 
International Working Group to enroll a 
homogenous population of early symptomatic 
patients whose memory deficit was likely due to 
underlying Alzheimer's pathology including 
patients whose MMSE was above 24 but had a 
deficit on the FCSRT memory test with CSF 
evidence of Aβ deposition and positivity on 
amyloid PET. Dosing in this trial was discontinued 
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on December 19, 2014, based on an interim futility 
analysis that suggested no benefit.  However, 
patients continued assessment and in July 2015, 
Roche reported that in the fastest progressors who 
also received the highest doses there was a trend 
towards benefit observed in ADASCog and MMSE 
scores, brain amyloid load, CSF total tau, and CSF 
p-tau measures. The main side effect was ARIA 
which was as high as 14% but was mostly 
asymptomatic and associated with gantenerumab 
dose and with the number of ApoE 4 alleles a 
patient carried. The trial now continues as an open 
label trial of the higher gantenerumab dose with an 
expected completion date in 2020. A second phase 
III trial initiated in 2014 is also ongoing with a 
higher dose and has completed recruitment of 389 
patients with mild AD and is expected to be 
complete in 2019 (Marguerite Road 
NCT02051608). Gantenerumab, together with 
solanezumab, is also being investigated by the 
Dominantly Inherited Alzheimer Network (DIAN). 
Crenezumab (MABT5102A) is another 
humanized monoclonal antibody under 
development for AD. Crenezumab is an IgG4 
monoclonal antibody which is expected to reduce 
pro-inflammatory activity and limit risk of 
vasogenic edema due to reduced effector functions 
on microglia (71). Crenezumab binds all forms of 
Aβ, including monomers, oligomers, and fibrils but 
binds with highest affinity to the oligomers and 
fibrils inhibiting aggregation and promoting 
disaggregation. Phase I trials were initiated in 2008 
and 2009 in a total of 78 patients (NCT00997919, 
NCT00736775).  No results have been published 
for phase I trials but safety and tolerability was such 
that a large multi-center 68-week phase 2 trial 
enrolling 448 patients in North American and 
Europe with mild to moderate AD was initiated in 
2011 and completed in 2014 (ABBY 
NCT01343966). In this study both subcutaneous 
and intravenous administration was assessed.  
Intravenous administration allowed for almost twice 
as much delivery of antibody as the subcutaneous 
administration as dosing was not limited by fears of 
T-cell mediated inflammation and resulting ARIA. 
Despite this increased drug exposure, ABBY did 
not show differences in primary clinical endpoints 
of cognitive change when assessing the total 
population of mild-to-moderate AD although 
further analysis suggested possible efficacy when 
only mild AD was considered. A 91-patient 
biomarker study called BLAZE was also completed 
in spring 2014 (NCT01397578) and both continue 
into an open-label extension trial of 361 patients 
that is expected to be completed in 2017 
(NCT01723826). The BLAZE study reported no 
differences in PET amyloid imaging between 
groups although differences were observed in CSF 
Aβ. A phase II trial aiming to evaluate the safety 
and efficacy of crenezumab in asymptomatic 
carriers of E280A autosomal-dominant mutation of 
PSEN1 for which pathological aggregation of Aβ 
appears at an age of approximately 25 commenced 
in November 2013 (NCT01998841). A phase III 
trial was initiated Mar 2016 in 750 patients with 
prodromal and mild AD (NCT02670083) and is 
actively recruiting.  
Aducanumab (BIIB037) is a monoclonal 
antibody targeting aggregated forms of Aβ protein, 
with high-affinity, fully human IgG1 monoclonal 
antibody against a conformational epitope found on 
Aβ. A phase Ib study of aducanumab in patients 
with prodromal or mild Alzheimer’s was 
completed, which showed a statistically significant 
reduction on amyloid plaque as well as a 
statistically significant slowing of clinical 
impairment. A second Phase Ib study however, 
could not replicate this and also show worsened 
safety data. In summer of 2012, PRIME, a 
multicenter, multiple-dose study in 166 people with 
prodromal or mild AD was initiated and interim 
results were promising enough that two 18-month 
phase III studies were initiated in 2015 with an 
expected completion date in 2022.  The ENGAGE 
and EMERGE studies will enroll 1,350 people with 
MCI due to AD or mild AD as ascertained by a 
positive amyloid PET scan each in sites in North 
America and Europe (NCT02484547, 
NCT02477800).  
Ponezumab (PF-04360365) is a humanized 
IgG2δA monoclonal antibody that unlike the other 
monoclonal antibodies binds the free carboxyl 
terminal of amino acids 33-40 of the Aβ 1-40 
peptide (72). Five phase I trials showed acceptable 
safety but two phase II trials concluded in 2011 
showed no treatment effect and development of 
ponezumab for AD is no longer being pursued 
although its use is being explored in patients with 
cerebral amyloid angiopathy.  
BAN2401 is a humanized IgG1 monoclonal 
antibody that binds selectively to large, soluble Aβ 
protofibrils and is thought to lead to their clearance 
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or neutralize their toxicity based on the discovery of 
the “artic mutation” in APP, which leads to a form 
of Alzheimer's disease with particularly high levels 
of Aβ protofibrils (73). A phase II, 18-month U.S. 
trial is enrolling up to 800 people who either have 
mild cognitive impairment due to AD, or who have 
probable AD and whose diagnosis is confirmed by a 
positive amyloid PET scan with the primary 
outcome being a change in a composite of cognitive 
tests (NCT01767311).   
Another approach closely related to passive 
immunotherapy of AD is IVIG (Gammagard) 
administration.  IVIG is a mixture of polyclonal 
antibodies prepared from the blood plasma of 
thousands of healthy young volunteers.  IVIG binds 
weakly to the monomeric form of Aβ and binds 
strongly to neurotoxic oligomers and Aβ fibrils. 
IVIG also has immune-modulating and 
inflammatory effects which may potentially target 
other AD mechanisms. A phase I trial in 8 patients 
showed reduction in cognitive decline in 7 patients 
that completed the trial and an improvement in 
cognition six patients. Phase II and III trials in 
patients with mild-to-moderate ensued but in 2012 a 
phase III trial of 10% IVIG in 360 patients, while 
generally safe and well-tolerated was terminated 
due to lack of efficacy.  Some positive results were 
noted in subgroups, especially among APOE-e4 
carriers and moderately impaired AD patients and 
recruitment is ongoing for further phase III trials 
(NCT01561053) in these populations (74, 75). 
Recently, two planned phase III studies 
(NCT01736579, and NCT01524887) were 
terminated, since the first Phase III study 
(NCT00818662) failed to show efficacy and 
confirmed the safety profile observed in Phase II 
studies.  
 
Secretase Inhibitors (γ and β) 
The β-site APP cleaving enzymes 1 and 2 (BACE1 
and BACE2) were initially identified as 
transmembrane aspartyl proteases cleaving the 
amyloid precursor protein (APP). BACE1 is a 
major drug target for Alzheimer's disease because 
BACE1-mediated cleavage of APP is the first step 
in the generation of the pathogenic amyloid-β 
peptides. However, BACE1 targeted drug-
development has been hindered, because the 
enzyme has been found to have many substrates 
with important physiological roles and initial non-
selective inhibition of the enzyme was found to 
have numerous toxic consequences (76). 
Furthermore, the active site of BACE1 is relatively 
large, and many of the bulky compounds that are 
needed to inhibit BACE1 activity are unlikely to 
cross the blood–brain barrier.  Therefore, much 
effort has been put into developing non-
peptidomimetic β-secretase inhibitors that show 
high BACE1 selectivity (BACE1/BACE2 
selectivity >100) with weak or non-peptide 
characteristics that favor CNS penetration and oral 
bioavailability (77). Many BACE inhibitors are still 
in the preclinical phase and only a few have entered 
clinical trials to date. Clinical trials involving β-
secretase inhibitors are summarized in Table 3. 
The BACE1 inhibitor furthest along in 
development is MK-8931, which is a diaryl amide-
substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide 
derivative and a small molecule inhibitor of 
BACE1/2 (with a higher affinity towards BACE1).  
The first phase I/II studies were completed in 2012 
(NCT01496170, NCT01537757) and demonstrated 
tolerability with dose-proportional increases in 
plasma and CSF exposure.  Importantly CSF Aβ 
was reported to be reduced by up to 92% (78). An 
18-month phase 3 trial (EPOCH, NCT01739348) 
enrolling 1,960 participants with mild to moderate 
AD patients was then initiated in 2012 followed by 
a second phase III trial (APECS, NCT01953601) 
enrolling 1500 patients with earlier stages of the 
disease (prodromal AD) in November 2013.  The 
EPOCH trial has finished recruitment and has an 
estimated primary completion date in 2017 with a 
final completion date in 2019 and the APECS trial 
is recruiting with an estimated primary completion 
date in 2019 and final study completion date in 
2021.  No preclinical or trial data has yet been 
published for this molecule with most information 
on its development being reported by the 
developing drug company.    
AZD3293 is an orally active, potent, highly 
permeable (able to penetrated BBB) inhibitor of 
BACE1 with unique slow off-rate kinetics that is 
hoped to translate into a prolongation of any 
observed effect beyond the turnover rate of Aβ. It 
has demonstrated time- and dose-dependent 
reductions of brain Aβ40 in mice, guinea pigs, and 
dogs as well as other tissue types (79). Reductions 
of up to 75% in CSF AB levels were reported in 
initial phase I safety findings announced in 
December 2013 and in at least ten other phase I 
studies that further evaluated safety, tolerability,  
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Table 2 - A summary of the clinical trials based on passive immunotherapy approaches (https://clinicaltrials.gov) 
Drug name Clinical Trial Number & Phase 
Start & End 
date 
Trial 
population outcome Special notes 
Bapineuzumab NCT00397891 - 
Phase I 
NCT00112073 - 
Phase II 
NCT00574132 - 
Phase III 
NCT00575055 - 
Phase III 
NCT00667810 - 
Phase III 
NCT00676143 - 
Phase III 
 
2006 - 2010 
 
2005 - 2008 
 
2007 - 2012 
 
2007 - 2012 
 
2008 - 2013 
 
2008 - 2012 
 
80 
 
234 
 
1331 
 
1122 
 
901 
 
1100 
Bapineuzumab was deemed to be relatively 
safe and well tolerated as half of the ARIA 
cases were asymptomatic, and half suffered 
only transient symptoms with just one patient 
requiring steroid treatment. In phase III both 
trials failed to show an effect on cognitive or 
functional primary outcomes or rate of brain 
volume loss. 
 
Solaneuzmab NCT00329082 -  
Phase II 
NCT00749216 - 
Phase II 
NCT01148498 - 
Phase II 
NCT00905372 - 
Phase III 
EXPEDITION1 
NCT00904683 -  
Phase III 
EXPEDITION2 
NCT01900665 - 
Phase III 
EXPEDITION3 
NCT01760005 -  
Phase III 
NCT02008357 -  
Phase III 
NCT02760602 -  
Phase III 
 
2006 - 2008 
 
2008 - 2009 
 
2010 - 2012 
 
2009 - 2012 
 
 
2009 - 2012 
 
 
2013 - 2020 
 
 
 
2012 - 2019 
 
2014 - 2020 
 
2016 – 2021 
 
19 
 
33 
 
55 
 
1000 
 
 
1040 
 
 
2100 
 
 
 
210 
 
1150 
 
2450 
 
 
-In phase II confirmed the antibody's safety 
and tolerability. 
- Phase III: ongoing 
Have reduced frequency of 
adverse effects such as ARIA 
compared to bapineuzumab. 
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Table 2 Continued… 
Gantenerumab NCT00531804 -  
Phase I 
NCT01656525 -  
Phase I 
NCT02133937 -  
Phase I 
NCT01636531 -  
Phase I 
NCT01224106 -  
Phase II/III 
NCT02051608 -  
Phase III 
 
   
2006 - 2010 
 
2012 - 2014 
 
2014 - 2014 
 
2012 - 2012 
 
2010 - 2019 
 
2014 - 2019 
 
60 
 
28 
 
31 
 
120 
 
799 
 
389 
It is generally safe and well-tolerated. 
Phase III: ongoing 
It is a fully human IgG1 
antibody that preferentially 
binds to aggregated Ab in the 
brain and vasculature with 
subnanomolar affinity and does 
not alter plasma Aβ. The main 
side effect was ARIA which 
was as high as 14% but was 
mostly asymptomatic and 
associated with gantenerumab 
dose and with the number of 
ApoE 4 alleles a patient carried. 
Crenezumab 
(MABT5102A) 
NCT00997919 - 
Phase I 
NCT00736775 - 
Phase I 
NCT01343966 -  
Phase II 
NCT01397578 - 
Phase II 
NCT01723826 -
Phase II 
NCT01998841 - 
Phase II 
NCT02670083 -
Phase III 
 
2009 - 2010 
 
2008 - 2010 
 
2011 - 2014 
 
2011 - 2014 
 
2012 - 2017 
 
2013 - 2020 
 
2016 - 2021 
 
22 
 
56 
 
448 
 
91 
 
360 
 
300 
 
750 
 IgG4 monoclonal antibody 
expected to reduce pro-
inflammatory activity and limit 
risk of vasogenic edema due to 
reduced effector functions on 
microglia 
Aducanumab 
(BIIB037) 
NCT01397539 -
Phase I 
NCT02434718 -
Phase I 
NCT02782975 -
Phase I 
NCT01677572 -
Phase I 
NCT02484547 -
Phase III 
NCT02477800 -
Phase III 
 
2011 - 2013 
 
2015 - 2016 
 
2016 - 2016 
 
2012 - 2019 
 
2015 - 2022 
 
2015 - 2022 
 
53 
 
20 
 
40 
 
197 
 
1350 
 
1350 
Statistically significant reduction on amyloid 
plaque as well as a statistically significant 
slowing of clinical impairment 
Human IgG1 monoclonal 
antibody against a 
conformational epitope found on 
Aβ 
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Table 2. Continued… 
Ponezumab (PF-
04360365) 
NCT00733642 -
Phase I 
NCT00455000 -
Phase I 
NCT01125631 -
Phase I 
NCT01005862 -
Phase I 
NCT00607308 -
Phase I 
NCT00722046 -
Phase II 
NCT00945672 -
Phase II 
NCT01821118 -
Phase II 
 
2008 - 2009 
 
2007 - 2009 
 
2010 - 2011 
 
2010 - 2012 
 
2008 - 2010 
 
2008 - 2011 
 
2009 - 2011 
 
2013 - 2015 
 
15 
 
37 
 
8 
 
17 
 
20 
 
198 
 
36 
 
36 
Acceptable safety Profile 
 
 
 
 
 
 
 
 
 
Phase II studies failed to show any 
significant therapeutic effect. It is no longer 
pursued for AD treatment.  
IgG2δA monoclonal antibody 
that (unlike the other 
monoclonal antibodies) binds 
the free carboxyl terminal 
amino acids 33-40 of the Aβ 1-
40 peptide 
BAN2401 NCT01230853 -
Phase I 
NCT02094729 -
Phase I 
NCT01767311 -
Phase II 
 
2010 - 2013 
 
2013 - 2015 
 
 
2012 - 2018 
 
80 
 
26 
 
 
800 
Well-tolerated, without incidents of ARIA 
 
 
 
 
Humanized IgG1 monoclonal 
antibody that binds selectively 
to large, soluble Aβ protofibrils 
IVIG 
(Gammagard) 
NCT00299988 -
Phase II 
NCT00812565 -
Phase II 
NCT01300728 -
Phase II 
NCT01561053 -
Phase II/III 
NCT00818662 -
Phase III 
NCT01736579 -
Phase III 
NCT01524887 -
Phase III 
 
2006 - 2010 
 
2009 - 2010 
 
2011 - 2017 
 
2012 - 2016 
 
2008 - 2012 
 
2012 
 
2012 
 
24 
 
58 
 
52 
 
350 
 
390 
 
6 
 
508 
 
 
 
 
 
 
 
 
 
Generally safe and well-tolerated; however, 
efficacy was not observed. 
Terminated, due to lack of efficiency 
 
Terminated, due to lack of efficiency 
A mixture of polyclonal 
antibodies prepared from the 
blood plasma of thousands of 
healthy young volunteers.  
IVIG binds weakly to the 
monomeric form of Aβ and 
binds strongly to neurotoxic 
oligomers and Aβ fibrils. 
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metabolism, and potential drug interactions of the 
compound (80). A large phase II/III trial began 
enrollment in September 2014, enrolling 2,202 
patients with MCI due to AD or mild AD, to be 
treated for 2 years and set to run for 5 years 
(AMARANTH, NCT02245737). In June 2016, a 
second phase III trial was initiated (DAYBREAK-
ALZ, NCT02783573) with target enrollment of 
1899 patients with mild AD only, also set to run 5 
years with a 3-year treatment period. 
JNJ-54861911 is another inhibitor of BACE1 
also in phase II/III trials. It was initially optimized 
through multiple steps by the Shionogi group in 
Japan from hits with amino-dihydrothiazine or 
modified versions of the cyclic isothiourea 
warhead. JNJ-54861911 first began phase I testing 
in 2013 and has undergone at least 11 phase I and 
phase II trials.  The inhibitor has been reported to 
be safe and well-tolerated with dose-dependent 
reductions in Aβ1-37, Aβ1-38, Aβ1-40, and Aβ1-42 
with 90% reduction in AB seen with the highest 
dose (81). In October 2015, a phase II/III study 
began in asymptomatic people at risk of developing 
Alzheimer's dementia (NCT02569398). This trial 
will enroll 1,650 participants in Europe, Australia, 
and Mexico. This trial will run until the year 2023. 
A long-term safety and tolerability study of 100 
patients from previous phase I /II trials is ongoing. 
E2609 is another BACE inhibitor that is also in 
development. It was initially developed through 
several series of bicyclic aminodihydrothiazines 
fused with unsaturated five- and six-membered 
rings, and has shown significant reduction in CSF 
and plasma levels of Aβ in non-human primates. At 
least eight phase I trials have been completed 
evaluating the safety and pharmacology of E2609 in 
nearly 500 healthy volunteers and people with early 
Alzheimer's disease including evaluation of the 
compounds effects on the heart and interactions 
with drugs commonly prescribed to the elderly. The 
drug shows a reduction of Aβ levels in plasma and 
a dose-dependent reduction of up to 80 percent in 
CSF Aβ levels with headache and dizziness being 
the most common adverse events although several 
cases of orolabial herpes relapse were observed (82, 
83). An 18-month phase II study in 700 people with 
MCI due to AD or prodromal AD who have a 
positive amyloid PET scan was initiated in 
November 2014 and results are expected in January 
2018 (NCT02322021). 
CNP520 is another oral inhibitor of BACE 
developed by Novartis that recently completed 
phase II trials (March 2016 in 125 healthy patients; 
NCT02576639).  It is also being currently evaluated 
in a phase II/III prevention study that will measure 
delay to diagnosis of MCI or AD dementia in 1340 
cognitively normal, homozygous ApoE4 carriers 
aged 60 to 75.  This study is somewhat unique in 
that, half of the participants will be randomized to 
either CNP250 or matching placebo, and the other 
half to CAD106 or placebo (NCT02565511). Many 
other BACE inhibitors have failed phase I/II trials 
including LY2886721 terminated in phase II in 
2013 after four cases of abnormal liver 
biochemistry values, LY2811376 terminated in late 
phase I due to damage to the pigment epithelium of 
the eye found in simultaneous rat toxicology studies 
and CTS21166, a small transition-state analog 
inhibitor that was the first to pass a phase I clinical 
trial in 2008 but whose development is not being 
continued for unknown reasons. Various BACE 
inhibitors including, GSK188909, have never gone 
beyond pre-clinical stage of development. 
γ-Secretases have also been evaluated in 
clinical settings. While the amyloidogenic pathway 
is initiated by BACE1, the γ-secretase enzyme is 
responsible for the final stage of amyloidogenesis, 
leading to the generation of Aβ1-40 and Aβ1-42 
and is consequently a target for AD treatment. 
However, substrate promiscuity promotes major 
off-target secondary adverse effects and has 
hindered development of γ -secretase inhibitors 
early on. For instance, Notch, a major protein 
responsible for regulating cell proliferation, 
development, differentiation, and cellular 
communication, is one of the targets of γ-secretase.  
Inhibition of Notch processing is responsible for 
adverse events seen with early γ -secretase 
inhibitors including severe gastrointestinal, 
hematopoietic side effects, and neurodegeneration 
and have been hampering the development of 
clinically useful γ-secretase inhibitors so far. 
Semagacestat (LY450139) is a γ-secretase 
inhibitor that reduces Aβ40 and Aβ42 production 
and was the first γ-secretase inhibitor to go into 
phase III clinical trials. In preclinical animal 
studies, semagacestat reduced both soluble Aβ and 
amyloid plaque burden. Phase I evaluated 
semagacestat in 27 healthy volunteers and showed 
dose-dependent reduction in AB synthesis in the 
CSF (84). Phase II trials, showed a greater number 
of skin-related side effects in the treatment group  
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including rash and lightening hair color. Despite these side effects, 
two 21-month phase III trials, IDENTITY-1 and IDENTITY-2, were 
initiated and enrolled a total of 3036 patients.  Both trials were 
terminated in April 2011 because of an increased risk of skin cancer 
and infections in the treatment group.  Moreover, cognition and 
function not only did not improve but worsened in all treatment 
groups (85). Failure of Semagacestat was believed to be due to the 
broad inhibition of 40-plus substrates of γ-secretase, particularly 
Notch, which was previously not well-known.  In particular, effects 
on cognition were believed to be due to the accumulation of the 
neurotoxic precursor of Aβ (the C-terminal fragment of APP or 
CTFβ) resulting from the block of the γ-secretase cleavage activity 
on APP (86).  
Table 3 - A summary of the clinical trials based on passive β-secretase inhibitors (https://clinicaltrials.gov) 
Special note Outcome Trial population Start & End date Clinical Trial 
Number & Phase  
Drug name  
No preclinical or trial data 
has been published 
ongoing  
1500 
 
2013 - 2021 
NCT01953601 -  
Phase III  
MK-8931 
  Ongoing  1899 patients with mild 
AD 
2016 - 2021 NCT02783573 -  
Phase III  
AZD3293 
Long term safety and 
tolerability study is still 
ongoing 
Ongoing   
1650 
 
2015 - 2023 
NCT02569398 -  
Phase II/III  
JNJ-54861911 
  Ongoing   
700  
 
2014 - 2018 
NCT02322021 
Phase II 
E2609 
  Ongoing   
1340 
November 2015- 
August 2023 
Phase II 
NCT02565511 
CNP520 
  Terminated in 2013 after 
four cases of abnormal 
liver biochemistry values  
 -  - Phase II LY2886721 
 Terminated in late phase I 
due to damage to the 
pigment epithelium of rat 
eye 
 -  - Phase I LY2811376  
The development is not 
continued for unknown 
reason(s)  
Passed phase I  -   - Phase I CTS21166 
Has never gone beyond 
preclinical stage of 
development  
 -  -   -  Preclinical   GSK188909 
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Avagacestat is another γ-secretase inhibitor 
which was discontinued as a result of a lack of 
efficacy (NCT00810147, NCT00890890, 
NCT00810147, and NCT01079819). Avagacestat 
was reported to selectively block processing of the 
enzyme's APP substrate with 137-fold selectivity 
for APP over Notch in cell culture, and to reduce 
CSF Aβ levels without causing Notch-related 
toxicity in animals (87, 88). About a dozen phase I 
trials evaluated the safety and pharmacology of 
avagacestat in healthy volunteers and people with 
Alzheimer's disease.  In particular, drug-interaction 
studies were conducted with cholinesterase 
inhibitors, blood thinners, and a range of other 
drugs commonly used in aging populations, 
including topical antibiotics and disinfectants.  In 
2009, two Phase 2 trials were started, of which one 
was completed, and the other was terminated. In the 
first multinational trial with 209 people with mild to 
moderate Alzheimer's disease many patients 
dropped out due to gastrointestinal and 
dermatological side effects and non-melanoma skin 
cancers were also seen. The trial generated a dose-
dependent pharmacodynamics model for the effects 
on CSF biomarkers in some patients, but at the two 
higher doses cognition trended toward a worsening 
compared with placebo (89). ARIA also occurred in 
some patients. In the second phase II trial, 
avagescat was evaluated in the prodromal 
population and showed similar results and the trial 
was terminated in 2012. 
Begacestat (GSI-953) was another γ-secretase 
inhibitor that went through pre-clinical 
development was, which was 16-times more 
selective for the inhibition of APP cleavage over 
Notch.  However, phase I trials (NCT00959881, 
NCT00547560) in healthy human volunteers only 
affected the plasma concentration of Aβ and not its 
CSF concentration and development was halted 
(90). Another compound, NIC5-15 (pinitol) is a 
naturally occurring cyclic sugar alcohol found in 
soy and several other plants and fruits. It is also 
believed to modulate γ-secretase that is selective for 
APP. A Phase 2a and 2b trial were completed in 15 
and 30 people respectively in 2013 and the 
compound was reported to indicate good 
tolerability, as well as stabilization of cognition as 
measured by the ADAS-Cog (NCT01928420). It is 
unclear if this is being pursued for further 
development. 
 
Some non-steroidal anti-inflammatory drugs 
(NSAIDs) such as tarenflurbil, act as γ-secretase 
modulators and shift the γ-secretase cutting point to 
produce shorter nontoxic Aβ fragments.  A phase II 
trial with the NSAID tarenflurbil in mild to 
moderate AD showed a significant improvement in 
primary outcome of global functioning and 
activities of daily living and a positive trend 
towards improved cognition with a statistically 
significant reduction in newly synthesized Aβ in 
human volunteers. Phase III trials were completed 
in 2008, and demonstrated an increased 
deterioration in cognition and activities of daily 
living compared to placebo-treated controls and it 
was discontinued. 
Compound CHF-5074, a molecule with a 
formulation based on the structure of R-
flurbiprofen, was being reported as a γ-secretase 
modulator that affected Aβ- and other amyloid-
related outcomes. Subsequent preclinical studies 
proposed other mechanisms of action, such as 
restoring neurogenesis, reorganizing the astrocytic 
cytoskeleton, reducing tau, rescuing synaptic 
plasticity, or acting on microglia to counteract 
inflammation (91). Three phase I clinical trials in 
144 healthy young men reported CHF-5074 to be 
safe and tolerable in these subjects; one notable side 
effect was mild diarrhea. Three phase II trials were 
conducted and the first reported trends toward 
improved executive function, were reported for 
carriers of the ApoE4 risk allele, but not non-
carriers (92). It is unclear if the agent is undergoing 
further development as the company awaits the 
outcome of licensing negotiations. 
There are many other γ-secretase inhibitors in 
preclinical development. BMS-299897 is another γ-
secretase inhibitor that has been tested in animal 
models. BMS-299897 blocked the increase in Aβ1-
42 content and decreased Aβ1-40 levels 
significantly in the Aβ25-35 mouse model of 
Alzheimer's disease (93). MRK-560 is also another 
γ-secretase inhibitor that is potent, orally 
bioavailable, and can penetrate the brain. MRK-560 
caused marked inhibition of both Aβx- 40 and Aβx-
42 in plasma, brain, and cerebrospinal fluid with 
good correlation between plasma and brain and 
plasma and CSF (94). Treatment of AD mice/rats 
with the γ-secretase inhibitor DAPT has also been 
studied and resulted in decreased Aβ levels in 
plasma and cerebrospinal fluid (CSF) (95). 
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Table 4 - A summary of the clinical trials based on passive γ-secretase inhibitors (https://clinicaltrials.gov) 
Special note Outcome Trial population 
Start & End 
date 
Clinical Trial 
Number & PhaseDrug name 
Reduces Aβ40 and Aβ42 
production  
First γ-secretase inhibitor to go 
into phase III clinical trials 
Terminated in April 2011 
Increased risk of skin cancer and 
infections 
Cognition and function not only did 
not improve but worsened in all 
treatment groups 
 
1111 
 
1537 
 
180 
 
2011 - 2008  
 
2011 - 2008  
 
2011 - 2009  
NCT00762411 - 
Phase III 
NCT00594568 -
Phase III 
NCT01035138 -
Phase III 
Semagacestat 
(LY450139) 
Selectively blocks processing of 
the enzyme's APP substrate 
with 137-fold selectivity for 
APP over Notch 
- GI and dermatological side effects 
and non-melanoma skin cancers 
- Terminated, due to lack of efficacy 
and similar side effects 
 
209 
 
263 
2009 - 2010 
 
2009 - 2013  
 
NCT00810147 -
Phase II 
NCT00890890 -
Phase II 
Avagacestat  
16-times more selective for the 
inhibition of APP cleavage over 
Notch 
Only affected the plasma 
concentration of Aβ and not its CSF 
concentration 
Its development was halted  
 
49 
 
47 
 
2007 - 2009 
 
2009 - 2009 
NCT00547560 -
Phase I 
NCT00959881 - 
Phase I 
Begacestat (GSI-
953) 
Naturally occurring cyclic sugar 
alcohol found in soy and 
several other plants and fruits 
Indicated good tolerability and  
stabilization of cognition as measured 
by the ADAS-Cog 
 
15 
 
30 
 
2007 - 2010 
 
2007 - 2014 
NCT00470418 -
Phase IIa 
NCT01928420 -
Phase IIb 
NIC5-15 
NSAID Increased deterioration in cognition 
and activities – Discontinued 
 
1600 
 
2008 - 2005  
NCT00105547 - 
Phase III 
Tarenflurbil  
It is not clear if it is undergoing 
further development 
safe and tolerable – Mild diarrhea 
 
 
 
 
 
Improved executive function for 
carriers of the ApoE4 risk allele but 
not non-carriers  
 
84 
 
48 
 
12 
 
96 
 
74 
 
51 
 
2010 - 2009  
 
2010 - 2010 
 
2011 - 2011 
 
2011 - 2012 
 
2011 - 2012 
 
2012 - 2013 
NCT00954252-Phase 
I 
NCT01203384-Phase 
I 
NCT01258452-Phase 
I 
NCT01303744-Phase 
II 
NCT01421056-Phase 
II 
NCT01602393-Phase 
II 
CHF-5074 
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Tau Targeted Therapies  
Aggregates of abnormally hyperphosphorylated tau 
are the components of neurofibrillary tangles, the 
hallmark lesion in AD other than beta-amyloid. Tau 
has more recently been emerging as potentially an 
equally important biological target for innovative 
AD therapies. Potential tau therapies include 
inhibition of tau phosphorylation, microtubule 
stabilization, prevention of tau oligomerization, and 
enhancement of tau degradation as well as tau 
immunotherapy. Most agents directed against the 
tau protein are still in preclinical tests, with only a 
handful having reached clinical trials.  
The tau therapy furthest along in development 
is TRX0237 also known as leucomethylthioninium 
(LMTX). This compound is a derivative of a well-
known Methylene Blue dye, i.e. methylthioninium 
chloride but was improved for enhanced 
bioavailability and tolerability (96). The purported 
action of both of these compounds is to act as tau 
aggregation inhibitors by not only inhibiting the 
formation of new oligomers, but more importantly 
to release soluble tau from oligomers and paired 
helical filaments in a monomeric form which is 
susceptible to proteases (97). In a large 12-month 
phase II study in 321 subjects, MTC was found to 
stabilize the progression of AD over 50 weeks in 
both mild and moderate AD (98). The more stable, 
reduced version of methylthioninium, LMTX, was 
tested in two parallel phase III studies in AD in 250 
centers in 22 countries world-wide enrolling 891 
patients with mild-to-moderate AD 
(NCT01689246) completed at the end of 2015 and 
in 800 patients with mild AD (NCT01689233) 
completed in June 2016. Of note, these therapies are 
also being tested in other phase III trials for another 
tauopathy, frontotemporal dementia 
(NCT01626378). The clinical trials based on tau 
targeted therapies are summarized in Table 5. 
Because tau is a component of microtubules 
and hyperphosphorylation of tau results in 
microtubule destabilization and resulting 
cytoskeleton degeneration, other agents of interest 
in AD are agents with microtubule stabilizing 
effects (99).  Agents that have been tested in phase I 
clinical trials include epothilone D (BMS-241027) 
and TPI-287.  Epothilone D (BMS-241027) is a 
small molecule taxane drug that has been 
previously studied in oncology and is capable of 
penetrating the blood–brain barrier and normalizing 
tau binding at low doses.  In tau transgenic animals, 
BMS-241027 restored microtubule dynamics to 
baseline levels with beneficial effects seen on 
performance in the Morris water maze deficits, tau 
pathology, and neurodegeneration (100).  However, 
BMS 241027 has undergone phase I trials in 40 
patients which were completed in October 2013 
(NCT01492374) and the agent has not been pursued 
further in AD development. TPI-287 is another 
tubulin-binding and microtubule stabilizing agent 
that is also a synthetic derivative of the taxane 
drugs used in oncology for various brain tumors. It 
is being tested in phase I trials in 33 patients in 
November 2013 that is currently recruiting AD 
patients for phase I study (NCT01966666). The 
study is set to run until March 2017.  A phase I 
study in another tauopathy, corticobasal 
degeneration (CBD), or progressive supranuclear 
palsy (PSP) was also initiated in 2014 
(NCT02133846). 
Similar to beta-amyloid, immunotherapy 
directed against the tau protein is also a target for 
development. Passive immunization with specific 
monoclonal antibodies directed against 
phosphorylated tau is being studied and are in 
various stages of pre-clinical testing (101, 102).  
Because active immunization against tau is much 
further along in development. Active immunization 
using human, recombinant, full-size, non-
phosphorylated tau protein has been associated with 
neurotoxicity in animal models, this has led to the 
development of modified peptides to actively 
immunize against Tau. AADvac1 is the first 
vaccine to undergo clinical trials for active 
immunization against tau in AD. AADvac1 is 
directed again shortened, non-native tau which is 
susceptible to aggregation and is targeted against 
amino acids 294 to 305 of the tau sequence derived 
from the regulatory domain driving the 
oligomerization of tau. An extra N-terminal 
cysteine residue is added to obtain attachment of the 
peptide to the keyhole limpet hemocyanin and 
coupled to using aluminum hydroxide carrier (103).  
Phase 1 trials in 30 patients with mild-to-moderate 
AD were conducted from 2013-2015. Two patients 
reportedly withdrew due to adverse events, 
including a viral infection which was followed by a 
seizure. Safety and tolerability however was 
deemed such that a 24-month phase II trial in 
patients with mild-to-moderate AD was initiated in 
December 2015 with an expected completion date 
2018. It intends to enroll 185 patients with mild AD 
J Pharm Pharm Sci (www.cspsCanada.org) 20, 184 - 225, 2017 
 
 
 
206 
(ADAMANT, NCT02579252). 
Another potential AD therapy in development 
which actively immunizes against the tau protein is 
the liposomal-based vaccine ACI-35. The vaccine 
contains 16 copies of a synthetic tau fragment that 
is phosphorylated at the protein’s pathological 
phosphorylation residues S396 and S404 and is 
anchored into a lipid bilayer. It uses the adjuvant 
MPLA (104). In pre-clinical studies it rapidly 
generated high titers of polyclonal IgG antibodies 
specifically directed against phosphorylated tau, 
rather than non-phosphorylated tau, reducing 
soluble tau as well as insoluble, aggregated tau in 
brain extracts (105). In December 2013, a phase 1b 
multicenter, double-blind, randomized, placebo-
controlled study of the safety, tolerability and 
immunogenicity of ACI-35 was initiated recruiting 
24 patients. The trial has been completed and 
results are pending (ISRCTN13033912). As 
hyperphosphorylated tau protein is prone to 
aggregation leading to loss of cytoskeletal 
microtubule-stabilizing properties and degeneration 
of neurons, potential compounds preventing tau 
phosphorylation are also of interest.  The most 
important protein kinase involved in tau 
phosphorylation is glycogen synthase kinase 3 beta 
(GSK-3β) whose enzyme activity is also reportedly 
up-regulated by neurotoxic Aβ. Multiple GSK-3β 
inhibitors are under development.  
Tideglusib (NP031112, NP-12) is an orally 
available small molecule drug of the 
thiadiazolidinone class.  It acts as an irreversible 
GSK-3β inhibitor that has been shown to reverse 
amyloid in brain and prevent cell loss and reduce 
spatial memory deficits in preclinical studies (106, 
107).  Phase IIa studies in 30 patients reported good 
tolerability except for a transient increase in serum 
transaminase levels (108).  However, the follow-up 
phase IIb trial was aborted in 201 of 306 patients 
with mild-to-moderate AD (ARGO, 
NCT01350362), because primary endpoints were 
not met. The drug continues to be evaluated in 
progressive supranuclear palsy which is considered 
a pure tauopathy. 
Insulin is also being studied in the treatment of 
AD.  Insulin has been proposed to play a role in 
multiple AD disease pathways including against Aβ 
toxicity, neuro-inflammation, and tau pathology.  
The role of insulin in tau pathology is believed to be 
due to its effects on the decreasing the activity of 
GSK-3, thereby leading to inhibition of tau 
phosphorylation. Nasal insulin is being explored 
specifically because this particular route of 
administration can effectively deliver insulin 
directly into the brain without the unwanted effect 
of increasing systemic insulin levels. Multiple small 
pilot studies have been conducted with nasal 
insulin.  These studies have reported benefit in 
cognition including improved verbal memory and 
attention, although these studies are small and 
inherently methodologically flawed (109-111). 
Differential effects of insulin by ApoE genotype 
has also been proposed (112). Phase II/III clinical 
trials which were initiated in 2013 are currently 
ongoing for Humulin R in patients with the mild 
form of AD and is expected to be completed in 
2017 (NCT01767909). 
The efficacy of the human insulin analogue 
glulisine (Apidra ®) is also being evaluated in 
patients with AD.  A phase II, single center, 
randomized, double-blind, placebo-controlled of 
intranasal glulisine enrolling 90 patients with mild 
cognitive impairment and probable mild AD was 
initiated in August 2015 and is expected to be 
completed in September 2017 (NCT02503501).  
Prior phase I studies showed that glulisine was well 
tolerated but failed to have an acute impact on 
cognition in ApoE4 carriers with AD (113). 
However, these studies were not powered to show 
effect. 
 
Neurotransmitter-based therapies 
Muscarinic agonists 
The muscarinic acetylcholine receptors are G 
protein coupled receptors which comprise 5 
subtypes, M1 - M5, that play an important role in 
attention, the sleep-wake cycle and memory (114-
116). M1 in particular, plays a pivotal role in 
cognition and memory and are distributed 
throughout the cortex and hippocampus. M1 
muscarinic receptors are believed to play an 
important role in the regulation of secretase 
activities and synthesis of Aβ peptide, and 
subsequent tau hyperphosphorylation and cognitive 
dysfunction (117, 118).  M1 receptor activation 
activates α-secretase and leads to increased 
secretion of sAPPa and subsequent inhibition α-
secretase which then decreases production of Aβ.  
M1 receptor activation is also believed to inhibit 
oxidative stress which leads to cell death.  As such 
M1 receptor agonists have been targets for drug 
development in AD.   
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Table 5 - A summary of the clinical trials based on passive γ-secretase inhibitors (https://clinicaltrials.gov) 
Drug 
Clinical Trial 
Number & Phase 
 
Start & End   
Date 
Trial 
Population Outcome Special note 
Leucomethylthioninium 
(LMTX) 
(TRX0237) 
NCT01689233 - 
phase III 
NCT01689246 -
Phase III 
 
2012 - 2016 
 
2013 - 2015 
 
800 
 
891 
 Tau aggregation inhibitor 
Epothilone D (BMS-
241027) 
NCT01492374 - 
Phase I 
 
2012 - 2013 
 
40 
Not being pursued for 
AD 
A small molecule taxane drug capable of 
normalizing tau binding 
TPI-287 NCT01966666 - 
phase I 
 
2013 - 2017 
 
33 
 Synthetic derivative of taxane drugs 
Active immunization 
(AADvac1) 
NCT02579252 - 
phase II 
 
2016 - 2019 
 
185 
 Active immunization against tau protein 
 
Tideglusib 
(NPO31112, NP-12) 
 
NCT00948259 -
Phase I/II 
NCT01350362 -
Phase II 
NCT02586935 -
Phase II 
 
2008 - 2009 
 
2011 - 2012 
 
2015 - 2017 
 
30 
 
306 
 
90 
Good tolerability (with 
transient increase in 
serum transaminase 
- Aborted in 201 of 306 
patients 
Irreversible GSK-3b inhibitor 
transient increase in serum transaminase 
levels 
Insulin NCT01767909 - 
Phase II/III 
 
2013 - 2017 
 
240 
Humulin® R U-100 Effects on the decreasing the activity of 
GSK-3 
Glulisine (human insulin 
analog) 
NCT01436045 -
Phase II 
NCT02503501 - 
Phase II 
 
2011-2013 
 
2015-2017 
 
12 
 
90 
 Failed to have an acute impact on cognition 
in ApoE4 carriers in phase I 
 
 
There are three types of M1 mAChR-targeting drugs currently in 
development, including orthosteric agonists, allosteric agonists, and 
M1 positive allosteric modulators (M1 PAM). 
The first generation of M1 receptor agonists bind to an 
orthosteric ACh-binding site. Xanomeline was an M1/M4 selective 
muscarinic receptor agonist evaluated in patients with probable AD.  
In phase II studies in 343 patients a significant treatment effect was 
seen in cognition, global function, and behavioral symptoms but 
almost 50% of patients in the high-dose arm discontinued treatment 
due to adverse events which were primarily gastrointestinal in nature
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believed to be due from non-selective binding of 
M1 and M2 (119). The clinical studies pursued 
based on different neurotransmitter-based therapies 
are summarized in Table 6. Other M1 muscarinic 
agonists include AF102B, AF150(S), and AF267B 
which are highly bioavailable, blood-brain barrier 
penetrant, partial agonists that elevate the non-
amyloidogenic amyloid precursor protein in vitro, 
decrease beta-amyloid levels in vitro and in vivo, 
and can inhibit beta-amyloid and oxidative-stress-
induced cell death in cell lines. These drugs also 
restored cognitive impairments in several animal 
models for AD (120). AF102B failed in clinical 
trials due to gastrointestinal side effects, confusion, 
and diaphoresis and AF267B failed to show 
efficacy in clinical trials and was discontinued. 
LY593093 is a newer M1AChR orthosteric agonist 
that demonstrates modest to no activity at the other 
muscarinic subtypes and displays efficacy in the in 
vivo models of cognition (121). However, it is 
unclear if it is being pursued for clinical trials. 
Allosteric compounds bind to allosteric binding 
sites and have a better selectivity for the M1 
subtypes than do the previously described 
orthosteric agonists. Allosteric compounds can be 
classified into regular agonists and M1-positive 
allosteric modulators (PAMs).  Allosteric agonists 
of the M1 receptor activate the receptor at a site 
distinct from the orthosteric ACh site which 
contributes to selectivity for M1 receptors.  Early 
allosteric agonists (e.g., AC-42) could not activate 
M1 receptors in systems such as brain slices and 
had poor solubility in a physiologic buffer system, 
which prevented the in vivo use.  Newer allosteric 
agonists, such as TBPB, were developed to be 
highly selective for M1, blood brain barrier 
penetrant, and also activate NMDA in hippocampal 
pyramidal neurons. TBPB promotes the processing 
of APP towards the non- amyloidogenic pathway, 
decreases Aβ production in vitro, and has been 
shown to improve cognition in animal models 
(122). 77-LH-28-1 is another potent, selective and 
CNS penetrant allosteric M1 agonist which was a 
structural analog of AC-42 that was reported to 
improve cognition in animal models (123) as did 
AC-260584 (124). However, it is unclear if any of 
these agents are being pursued for clinical 
development. A unique agent is AF710B, which is a 
highly potent and selective allosteric M1 muscarinic 
agonist while also being a σ1 receptor agonist. 
AF710B was a potent and safe cognitive enhancer 
in animal models, while also reportedly decreasing 
BACE1, GSK3β activity, neuro-inflammation, 
soluble and insoluble Aβ40, Aβ42, plaques and tau 
pathologies (125).  While AF710B is believed to 
have much promise as a potential therapy in AD, it 
has not yet entered clinical phases of development. 
Currently, the only M1 receptor agonist that is in 
clinical trials is HTL9936 which completed the 
phase I trials in 2014 (NCT02291783). 
The M1 PAMs group cannot activate receptors 
directly, but can change the receptor conformation 
after binding, which then leads to a change in the 
ligand-binding and functional properties of the M1 
receptors. These muscarinic agents then have a 
novel and highly targeted mode of action and act 
only on a single muscarinic receptor subtype which 
is functioning sub-optimally and therefore be of use 
therapeutically in the early stages of AD. Therefore, 
M1 PAMs are active in the presence of the 
endogenous neurotransmitter Ach and inactive in its 
absence, which theoretically aids in the reduction of 
side effects.  Brucine was one of the first PAMs 
identified and was capable of selectively enhancing 
the effects of acetylcholine at M1 receptors by an 
allosteric mechanism (126). There are several other 
PAMs that act on M1, such as VU0029767 and 
VU0090157 which were previously in preclinical 
development (127).  ML169 is a M1 PAM which 
has more recently been in preclinical developed 
(128).  No M1 PAMs are currently in clinical trials. 
 
Nicotinic agonists 
The role of nicotinic receptors in AD is less clear 
than muscarinic agonists, but it is known that 
nicotinic acetylcholine receptors (nAChRs) play 
diverse roles in cognition, memory, and neuro-
protection (129). Unlike muscarinic receptors, 
which are G-protein coupled receptors, nicotinic 
receptors are ligand-gated ion channels.  The 
therapeutic nicotine effect is secondary to increased 
release of ACh through the activation of nAChRs 
and the subsequent activation of M1 receptors by 
acetylcholine (130). Studies have shown that α7- 
nicotinic agonists attenuate Aβ mediated toxicity 
but may increase phosphorylation of tau (131, 132).  
Many novel ligands for α7-nicotinic AChR have 
reached phase III development. 
EVP-6124 (also known as encenicline 
hydrochloride) is a novel selective α7-nAChR 
partial agonist that was evaluated for the treatment 
of cognitive deficits in both schizophrenia and AD 
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that very recently failed phase III trials.  In AD, an 
initial ascending-dose phase I/II study showed 
smaller doses of 0.1 to 1 mg/day of EVP-6124 (0.1 
to 1mg/day) to be safe and well-tolerated in 49 
people with mild to moderate AD for 28 days. 
Secondary efficacy endpoints at that time suggested 
that EVP-6124 could improve attention, verbal 
fluency, and executive function, when given in 
conjunction with acetylcholinesterase inhibitors 
(133).  As such, a 24-week phase II trial 
(NCT01073228) was conducted in 409 people using 
higher doses in mild to moderate AD patients and 
met most of its primary and secondary endpoints, 
including cognitive measures (134).  This led to the 
initiation of two international phase II trials 
enrolling a total of 958 patients with mild to 
moderate AD who were already taking an 
acetylcholinesterase inhibitor in October 2013 
(NCT01969123 and NCT01969136). The trial 
compared two fixed, undisclosed add-on doses of 
EVP-6124 to placebo and was set to run through 
2016 with results being available in 2017.  
However, in September 2015, the FDA placed a 
hold on these trials due to reports of rare but serious 
gastrointestinal side effects.  Phase III studies in 
schizophrenia continued as these patients did not 
seem to suffer from the same gastrointestinal side 
effects, but after the drug missed its co-primary 
endpoints in the schizophrenia phase trials, the 
development of this compound was discontinued. 
ABT-126, also known as nelonicline, is another 
α7-nAChR allosteric modulator that has undergone 
extensive clinical development.  It is similarly being 
tested in schizophrenia and Alzheimer's disease. 
Phase 1/2 research for ABT-126 began in 2009.  
The compound was compared to both placebo and 
to donepezil and preliminary data was reported to 
have shown good tolerability for ABT-126, with 
side effects similar to donepezil (135). In 2012, two 
24-week Phase 2b trials in 400 patients each, 
compared ABT-126 added on to donepezil to 
placebo, and compared ABT-126 monotherapy to 
placebo (NCT01549834). However, although ABT-
126 was generally well tolerated with the most 
common adverse events were agitation, 
constipation, diarrhea, fall, and headache, ABT-126 
did not demonstrate significant improvement in the 
primary efficacy endpoint and a treatment effect 
was not observed for any secondary efficacy 
measures of cognition, function, or global 
improvement (136). 
Serotonin antagonists 
Serotonin indirectly affects neurodegenerative 
processes. 5-HT6 serotonin receptors in humans are 
present in areas responsible for memory and 
cognitive function.  Blockade of 5-HT6 receptors 
increases synaptic acetylcholine release, improving 
cholinergic transmission and enhances memory and 
cognition (137-139). Antagonists of 5-HT6 are 
under development for AD. Idalopirdine (Lu 
AE58054) is a 5-HT6 that has been reported to be 
highly selective, aside from some affinity for 
adrenergic receptors (140). Lu AE58054 has 
successfully undergone phase I trials in healthy 
volunteers. Since the results of preclinical tests 
suggested that the use of 5-HT6 antagonists in 
combination with cholinesterase inhibitors may 
increase the beneficial effects of both drugs on 
cognition, a phase II study with idalopirdine and 
donepezil was carried out among 278 patients with 
moderate AD.  Results indicated improvement of 
cognitive function, although in 14 people taking 
idalopirdine transient increases in liver 
transaminase levels were observed (141).  Two 
Phase III studies evaluating the efficacy of 
LuAE58054 were initiated in 2013 enrolling 932 
patients (STARSHINE, NCT01955161) and 858 
patients (STARBEAM, NCT02006641) with mild-
to-moderate AD also on donepezil therapy.  These 
studies have completed recruitment and are 
expected to be completed in 2017.  An open-label 
extension phase III study for these trials were 
initiated in 2014 and this trial will also evaluate 
psychiatric endpoints (NCT02079246). 
Another 5-HT6 receptor antagonist, SB-742457 
also known as RVT-101 has also reached phase III 
trials. In animals, SB-742457 has been reported to 
not only have beneficial effects in AD models, but 
also in age-related cognitive decline in rats (142).  
SB-742457 was also studied in patients with or 
without donepezil in phase II clinical trials 
completed in 2011 (NCT00710684).  In the studies 
evaluating SB-742457 alone, no benefit was seen in 
cognition, but a significant improvement in global 
function was seen in those studies that evaluated 
patients also receiving donepezil (143). A phase III 
trial was initiated in 2015 enrolling 1150 patients 
with mild-to-moderate AD who are also stable on 
donepezil (MINDSET; NCT02585934). This trial is 
expected to be complete in 2017. Also, a phase II 
trial in patients with dementia with lewy body 
disease was initiated in January 2016 (HEADWAY-
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DLB; NCT02669433). SUVN-502 is a selective 
antagonist of the 5-HT6 serotonin receptor that is 
currently recruiting for phase II human trials.  In 
September 2015, a phase 2a proof-of-concept trial 
began enrolling 537 patients with probable 
Alzheimer's disease to compare SUVN-502 to 
placebo, all given in addition to donepezil.  The 
treatment period of the trial is to last 26 weeks and 
the study is expected to be complete in June 2017 
(NCT02580305).  
Other 5-HT receptor subtypes have been 
studied in AD but have failed to show benefit.   For 
instance, lecozotan, a 5-HT1a receptor antagonist 
which was shown to produce significant 
improvement in task performance efficiency and 
reverse learning deficits in animals (144), went as 
far as phase II/III studies (NCT00277810); 
however, it was not pursued further for AD 
development. Another orally active 5-HT1a 
receptor antagonist that was triggering some interest 
was called xaliproden, which was reported to 
counteract Aβ-induced neuronal toxicity and 
memory deficits in rats (145). However, two 18-
month Phase 3 trials in mild-to-moderate 
Alzheimer's disease, one enrolling 1,455 patients, 
the other 1,306 completed in 2007, found no 
beneficial therapeutic effect (NCT00104013 and 
NCT00103649). 
 
Histamine antagonists 
Histamine H3 receptors (both auto- and hetero-
receptors) are also present in large amounts in the 
prefrontal cortex, hippocampus, and hypothalamus 
which are important for memory and cognition.  
Blockage of the pre-synaptic H3 receptor leads to 
increased release of acetylcholine, dopamine, 
GABA, noradrenaline and histamine into the 
synaptic cleft, indirectly improving cholinergic 
neurotransmission (146).  ABT-288, a competitive 
selective H3 receptor antagonist was a 
histaminergic antagonist that reached phase II trials 
in 242 patients with mild to moderate AD 
completed in 2011.  Unfortunately, the trial was 
terminated early, as no statistical changes in 
cognitive function was found and because futility 
criteria were met (147). GSK239512, another H3 
antagonist with an acceptable safety profile, 
underwent phase II trials in 196 patients with mild 
or moderate AD (NCT01009255).  In this 16-week, 
double-blind, randomized, parallel group study, 
GSK239512 improved Episodic Memory; however, 
no improvements were observed in any other 
domains of cognition or other secondary endpoints 
indicating that H3 agonists at most, have modest 
and selective effects on cognitive function in 
patients with mild-to-moderate AD (148). Finally, 
dimebon is an antihistamine that has been used in 
Russia since the 1980s to treat allergic rhinitis, 
which made it to phase III trials in AD.  Dimebon is 
a pleiotropic drug with activities beyond blocking 
H1 histamine receptors. A mechanism of action for 
cognitive benefit has never been conclusively 
established; however, a broad spectrum of effects 
has been proposed including modulation of NMDA 
glutamate receptors, α-adrenergic receptors, and 
serotonergic or dopaminergic receptors (149).  
Phase I and II trials of a total of 197 Alzheimer's 
patients in Russia showed Dimebon was safe, well 
tolerated, and significantly improved the clinical 
course of patients with mild-to-moderate AD (150).  
This was then followed by two Phase III trials 
initiated in 2009 in patients with mild to moderate 
AD conducted in the Americas, Europe, Australia, 
and New Zealand, but neither Phase III study 
detected change in any primary or secondary 
outcome (NCT00838110, NCT00675623, and 
NCT00829374; CONNECTION). 
 
Neurotrophic and Hematopoietic Growth 
Factors 
Brain-Derived Neurotrophic Factor 
Brain-derived neurotrophic factor (BDNF) is a 
member of neurotrophins family, which are formed 
through post-translational modifications to 
proneurotrophins. It has been suggested that BDNF 
could play an important role in AD, due to 
promotion of neuron survival and synaptic 
regulation via TrkB receptor and PIEK/Akt 
signaling pathway (151). It has been linked to 
learning and memory, due to its role in axonal 
sprouting, dendritic proliferation, and neuronal 
differentiation (152). Loss of BDNF function has 
been reported in neurodegenerative and psychiatric 
diseases (153, 154). Genetic structure and 
intracellular mechanisms of BDNF was recently 
reviewed by Adachi et al (155).   
Multiple studies have revealed a drop in BDNF 
levels in AD patients (156-159), while other reports 
indicate an increase in BNDF expression compared 
to control (160), which could be a compensatory 
repair mechanism during early stages of AD.  
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Table 6 - A summary of the clinical trials based on neurotransmitter-based therapies (https://clinicaltrials.gov) 
Drug Clinical Trial Number & Phase 
Start & End   
Date 
Trial 
Population Outcome Special Note 
HTL9936 NCT02291783 -Phase I 
 
2013 - 2014 
 
108 
 M1 receptor agonist 
EVP-6124 
NCT00766363 -
Phase I 
NCT01073228 -
Phase II 
NCT01969123 -
Phase III 
NCT01969136 -
Phase III 
NCT02327182 -
Phase III 
NCT02004392 -
Phase III 
 
2008 - 2009 
 
2010 - 2012 
 
2013 - 2017 
 
2013 - 2017 
 
2014 - 2015 
 
2014 - 2017 
 
49 
 
409 
 
474 
 
403 
 
117 
 
348 
 
- Well-tolerated - improved 
attention, verbal fluency 
- Met most of primary and 
secondary endpoints 
- Terminated 
 
- Terminated 
 
- Terminated 
 
- Terminated 
α7 nAChR partial agonist 
for the treatment of cognitive deficits in both 
schizophrenia and AD given in conjunction 
with acetylcholinesterase inhibitors 
 
ABT-126 
nelonicline 
NCT00948909 -
Phase II 
NCT01549834 -
Phase II 
NCT01527916 -
Phase II 
NCT01676935 -
Phase II 
NCT01690195 -
Phase II 
 
2009 - 2010 
 
2012 - 2013 
 
2012 - 2013 
 
2012 - 2014 
 
2012 - 2014 
 
274 
 
434 
 
438 
 
349 
 
343 
 
- Good tolerability 
 
- No significant improvement 
 
- No significant improvement 
 
- Terminated 
 
- Terminated 
α7-nAChR allosteric modulator 
Idalopirdine 
(Lu AE58054) 
NCT01019421 -
Phase II 
NCT01955161 -
Phase III 
NCT02006641 -
Phase III 
NCT02079246 -
Phase III 
NCT02006654 - 
Phase III 
 
2009 - 2011 
 
2013 - 2017 
 
 
2014 - 2017 
 
2014 - 2017 
 
2014 - 2017 
 
278 
 
932 
 
 
858 
 
1770 
 
734 
 
- Improvement of cognitive function 
(with donepezil) Highly selective for 5-HT6, aside from some 
affinity for adrenergic receptors 
 
 
 
 
J Pharm Pharm Sci (www.cspsCanada.org) 20, 184 - 225, 2017 
 
 
 
212 
Table 6. Continued… 
SB 742457 
(RVT-101) 
NCT00710684 - 
phase II 
NCT02585934 -
Phase III 
 
2008 – 2011 
 
2015 - 2017 
 
684 
 
1150 
 - No benefit alone; significant 
improvement with donepezil 
Beneficial effects in AD models but also in 
age-related cognitive decline in animals 
SUVN-502 NCT02580305 - Phase II 
 
2015 - 2017 
 
537 
With donepezil  
lecozotan NCT00277810 - phase II/III 
 
2006 - 2008 
 
250 
Not pursued further for AD 
development 5-HT1a receptor antagonist 
xaliproden 
NCT00104013 - 
Phase III 
NCT00103649 - 
phase III 
 
2003 - 2007 
 
2003 - 2007 
 
1455 
 
1306 
 
- No treatment effect 
 
- No treatment effect 
5-HT1a receptor antagonist reported to 
counteract Aβ-induced neuronal toxicity and 
memory deficits in rats 
ABT-288 NCT01018875 -Phase II 
 
2009 - 2011 
 
242 
- Terminated; no change in 
cognitive function  
Competitive selective H3 receptor antagonist 
GSK239512 
NCT01009255 - 
phase II 
2009 - 2010 196 Modest and selective effects on 
cognitive function in patients with 
mild-to-moderate AD 
H3 antagonist 
Dimebon 
NCT00838110 - 
Phase III 
NCT00675623 - 
Phase III 
NCT00829374 -
Phase III 
 
2009 - 2010 
 
2008 - 2009 
 
2009 - 2011 
 
742 
 
598 
 
1003 
No change in any primary or 
secondary outcome 
Antihistamine used in Russia since the 1980s 
to treat allergic rhinitis 
 
 
Overall, it has been hypothesized that activating BDNF 
intracellular signaling could be a promising strategy in AD treatment 
(151). In 2013, Xu et al. reported a positive effect of a variety of 
flavonoids on expression levels of BDNF (161). Recently, Diaz-
Gerevini et al. reported a link between flavonoid resveratrol and 
enhancement of synthesis and mechanism of BDNF (162). Another 
possible pharmacological intervention that could positively affect 
BDNF levels is curcumin. Curcumin has been extensively studied for 
anticancer, antioxidant, and anti-inflammatory properties (163). 
However, it has been suggested that curcumin could also inhibit 
DNA methyltransferase, histone acetyltransferase and histone 
deacetylase, and modulate miRNA in hippocampus, which are 
associated with an increase in BDNF levels (164). Antidepressants 
have also reported to increase BDNF levels in AD patients (165). 
However, a recent clinical trial showed no significant effect of 
donepezil treatment on BDNF levels (166), while a 2009 clinical trial 
have indicated an increase in BDNF levels in lithium-treated patients 
with early AD (167). BDNF levels have been analyzed as a biomarker 
in other clinical trials conducted on AD treatment, especially in trials on 
the effect of physical activity and exercise on AD (168-170). Beneficial 
effect of BDNF in several mouse models of AD has also been reported. 
Delivering the BDNF gene in transgenic mice that constantly produces 
BDNF, has interfered with loss of synapses, and enhanced the cognitive 
function, without co-interacting with β-amyloid (171). 
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Nerve Growth Factor  
Another member of neurotrophic factors is nerve 
growth factor (NGF), which is a glycoprotein 
synthesized from the inactive form, pro-NGF (172), 
and exerts its trophic effect via TrkA and P57 
receptors (173). NGF plays an important role in 
maintaining neuronal proliferation and growth of 
neurons by interacting with other growth factors, 
and maintenance of cholinergic neurons and 
memory-related parts of CNS (e.g., hippocampus) 
(174). A drop in NGF levels with aging has been 
reported in many animal models (175-177), which 
could be an indication of the beneficial effects of 
NGF in AD patients. However, recent studies have 
not revealed a significant difference in blood, CSF, 
and brain levels of NGF in AD patients compared 
to healthy subjects (178). In a small phase I clinical 
study (8 patients) reported in 2005, transfected 
fibroblasts with permanent expression of NGF were 
implanted in the forebrain of the patients, and 
significant increase in neuronal activity was 
reported (179). Also, a more recent Phase I clinical 
study with ex vivo gene delivery to AD patients 
demonstrated enhanced cerebral metabolism and 
cognitive function without significant adverse 
effects (180). Positron emission tomographic (PET) 
scans confirmed the inhibition of the metabolic 
decline expected in AD patients.  
 
Glial-Derived Neurotrophic Factor 
Originally isolated from medium of a rat glioma 
cell line, glial-derived neurotrophic factor (GDNF) 
is another important growth factor, especially for 
survival and maintenance of dopaminergic neurons 
in midbrain (181). GDNF also seems to play a 
major role in enhancing the blood brain barrier. 
However, the neurotrophic effect of GDNF is only 
observed in the presence of transforming growth 
factor β (TGFβ) (182). The CSF levels of GDNF 
has shown a significant increase in AD patients 
(despite a decrease in serum levels of this growth 
factor), which has been explained as an adaptive 
process to enhance neurotrophic effect (183). Other 
researchers have reported an increase in GDNF 
plasma levels in AD patients (184). It has been 
indicated that treatment with GDNF could protect 
rabbits against AD-like symptoms, mainly by 
increasing the expression level of anti-apoptotic 
proteins (185). Also, transfection with GDNF-
expressing gene using a lentiviral vector has 
improved cognitive mechanisms in a transgenic 
mice model of AD (186). Maybe even more 
interestingly, this study has also demonstrated an 
increase in BDNF expression level, which might 
indicate a link between the two growth factors in 
their protective role against neuron degeneration.  
 
Granulocyte–Colony Stimulating Factor 
A potent growth factor with a stimulating effect on 
myeloid cells, granulocyte-colony stimulating 
factor (G-CSF), is also reported to inhibit apoptosis 
and induce neuronal differentiation in vitro (187). A 
decrease in G-CSF blood levels in early AD 
patients has been reported by Laske et al, with no 
data available for the CSF or brain level of this 
growth factor (188). Tsai et al. have reported a 
significant cognitive improvement in transgenic 
mice models of AD after 5 days of subcutaneous 
injection of G-CSF (189). They also reported that 
G-CSF administration induced neurogenesis around 
Aβ aggregates in these acute and chronic animal 
models of Aβ-driven AD. In 2012, a pilot clinical 
study in 8 patients with mild to moderate stages of 
AD did not show a serious adverse effect for five 
days of subcutaneous G-CSF administration, but 
did provide evidence for positive changes in 
hippocampal-dependent cognitive tasks (190).    
 
Stem Cell Factor 
Stem cell factor (SCF) is a hematopoietin expressed 
in CNS that enhances neurogenesis (191). It might 
also have a role in survival and migration of neural 
stem cells (192). Along with G-CSF it helps bone 
marrow-derived progenitor cells differentiate to 
microglial cells or neuronal stem cells (192). This 
suggests a protective role towards neurons, which 
might be exerted via PI3K/Akt or MEK/ERK 
pathways (193). A decrease in plasma and 
cerebrovascular fluid levels of SCF has been 
reported in AD patients (194). It has also been 
shown that a higher SCF level correlates with 
slower deterioration of cognition in AD patients 
(195).   
 
Antioxidant Therapies 
There is significant evidence for involvement of 
oxidative stress in the early stages of AD, as well as 
activation of signaling pathways that contribute to 
lesion formation and neuron degeneration (2). In 
fact, oxidative stress and glycoxidation are closely 
associated with AD development (196). Also, many 
preclinical and small clinical studies have shown 
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that antioxidant drugs have significant effect on the 
development of Alzheimer's disease. Reports show 
antioxidants could contribute to breaking down 
superoxide radicals and hydrogen peroxide 
compounds, and prevent them from damaging the 
neurons (197).  
 
Vitamins 
Vitamin E: As a free radical scavenger, alpha 
tocopherol or vitamin E acts as an antioxidant and 
has been studied in AD treatment. In 1996, Sano et 
al. reported a randomized double-blind, placebo-
controlled clinical study, which showed some 
benefit for vitamin E administration to AD patients 
(58% chance of death, institutionalization, change 
to a Clinical Dementia Rating of three, or loss of 
two basic activities of daily living within two years 
for recipients of 2000 IU/day vitamin E compared 
to 74% for patients who received placebo) (198). In 
another clinical study published more than a decade 
later, however, patients who received 800 IU 
vitamin E per day and did show a reduction in 
oxidative stress, no significant difference compared 
to placebo group was observed in terms of Mini-
Mental State Examination (MMSE) score after six 
months (199). However, a recent meta-analysis of 
different medical and dietary interventions in AD 
patients has demonstrated a protective effect for 
vitamin E (200). The potential effect of vitamin E 
on cognitive function of AD patients was recently 
reviewed by La Fata et al (201).  
 
Vitamin C: Ascorbic acid (vitamin C) is an 
important antioxidant in intracellular functions, 
with some of highest concentrations in CNS (202). 
It easily reacts with reactive oxygen species to 
neutralize their activity, and become ascorbate free 
radical, which is then recycled (203). Vitamin C 
seems to play an important role in neuronal repair, 
generation of new cells, and expression of many 
different genes (204). In a longitudinal study on 71-
93 years old Japanese-American men, the results 
suggested that vitamin E and C supplement intake 
might have a protective effect against vascular 
dementia and may improve cognitive function in 
elderly patients (205). More interestingly, the 2004 
Cache County study indicates that only the 
combination of vitamins C and E could reduce the 
risk of AD (206).  
 
Vitamin A and Carotenoids: A lipid-soluble 
antioxidant, vitamin A is synthesized in the body 
from structurally more complex carotenoids in our 
diet. Several studies have indicated a decrease in 
plasma levels of vitamin A and α-carotene (but not 
β-carotene) in AD patients compared to control 
individuals (207). However, there have been reports 
on the positive effect of β-carotene on cognitive 
function (208), and a correlation between higher β-
carotene plasma levels and memory in elderly 
individuals (65-94 years old) (209). In 2004, Ono et 
al. reported vitamin A and β-carotene would inhibit 
the formation of β-amyloid fibrils in vitro, and even 
destabilize already formed fibrils in a dose-
dependent manner (210). Also, vitamin A 
deprivation could cause β-amyloid accumulation 
(211) and memory deficit (212) in adult rodents. 
The role of carotenoids in prevention of AD 
symptoms and delaying of AD symptoms was 
recently reviewed by Obulesu et al. (213).  
 
Vitamin B12: Low levels of vitamin B12 are 
shown to be associated with neurodegenerative 
disease and cognitive impairment (214). Meta-
analysis studies indicate a lower level of vitamin 
B12 in AD patients (215), and a recent study 
indicates that administration of vitamin B12, along 
with other vitamins, selenium, and phospholipids 
could preserve synaptic function (216). In 2014, Li 
et al. performed a systematic review and meta-
analysis on efficacy of vitamin B supplementation 
in AD (217). Their results did not confirm the 
efficacy of vitamin B family in improving cognitive 
function, and authors concluded that these vitamins 
are unable to stabilize or slow decline in cognition 
in AD patients. 
 
Other Antioxidants 
Omega 3 polyunsaturated fatty acids, e.g., 
eicosapentaenoic acid (ESA) and docosahexaenoic 
acid (DHA) have been known to improve brain 
function, and therefore, there has been suggestions 
on their role in preventing neurodegenerative 
diseases, including AD. In fact, insufficient DHA 
intake has been related to brain aging, and reports 
suggest a positive effect for DHA in delaying the 
onset of AD (218). DHA is selectively accumulated 
in synaptic membranes and oligodendrocytes (219). 
A decrease in DHA brain levels in AD patients is 
also reported (220). Several clinical studies indicate 
beneficial effects of omega 3 in AD, which have 
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been recently reviewed by Thomas et al (221). 
Alkaloids, including caffeine, have also been 
studied extensively for their potential effect on AD 
progression. However, the results of observational 
studies vary significantly, and are therefore 
inconclusive (222). Gingko biloba, a natural plant 
containing flavonoids and terpenoids, has both 
antioxidant and anti-inflammatory properties, as 
well as free radical scavenging ability, can reduce 
amyloid precursor protein and inhibit Aβ 
aggregation (223). 
Metal chelators, glutathione peroxidases, SOD 
enzymes, antioxidant enzyme MnSOD, repair 
enzymes such as lipases, proteases, and DNA repair 
enzymes play important roles in neuronal survival 
and could protect brain tissue against oxidative 
damage (2). Melatonin, a pineal gland hormone 
with well-known role in sleep regulation, easily 
passes BBB, is a scavenger of hydroxyl, carbonate, 
alkoxyl, peroxyl and aryl cation radicals, and 
stimulates activities of antioxidative enzymes, 
which suggests a protective role in 
neurodegenerative disorders (224). It is also 
hypothesized that the higher AD prevalence in 
women could be related to reduction of estrogen in 
postmenopausal stage (225). Xu et al meta-analysis 
has also shown a protective role for estrogen in AD 
(200). 
 
CONCLUSION 
 
It has long been recognized that the anti-
Alzheimer’s drugs currently available for treatment 
modify only the late downstream effects of the AD 
pathophysiologic process and only temporarily 
reduces symptoms with no effect on disease 
progression.  Drug development scientists have 
long sought therapeutic approaches that target the 
etiologic processes of AD which can then 
ultimately affect disease progression.  The past two 
decades has seen rapid growth in the understanding 
of the underlying mechanisms involved in the 
etiology of AD, including the role of Aβ and tau, 
the role of various neurotransmitters, and the role of 
growth factors and antioxidants.  This has led to the 
development and testing of hundreds of molecules 
and numerous approaches targeted within these 
mechanistic categories including active and passive 
immunization against Aβ and tau, inhibition of Aβ  
aggregation through BACE-1 and y-secretase 
inhibition,  modulation of various neurotransmitter 
systems with subsequent effects on Aβ and tau 
pathology along with symptomatic effects, and 
finally administration of various growth factors and 
antioxidant therapy for promotion of neuronal 
survival against a now-recognized wide-reaching 
and complex neurodegenerative process.  Many of 
these molecules and approaches have been 
promising enough to be advanced to human testing 
in close to two thousand phase I-III clinical trials 
with the most promising agents in these categories 
reviewed in this article.  
Despite this immense effort, no new drugs have 
been approved for market, since the approval of 
meantime in 2003. As reviewed in this article, 
scientists have faced multiple challenges in this era 
of failed AD drug development.  Some challenges 
were overcome by strategic drug design, as seen in 
the development of active Aβ vaccines and the 
challenge of overcoming cerebral vasogenic edema 
caused by T-cell immunogenicity ultimately 
accomplished by targeting smaller non-T-cell 
immunogenic peptide sequences, or as seen in non-
selective NOTCH inhibition in BACE-1 therapeutic 
approaches which was overcome by design of 
highly selective BACE-1 inhibitors. However, 
despite careful honing of drug design, optimization 
of pharmacodynamics and pharmacokinetics, and 
significant modifications that introduced reduction 
in toxicity, no new AD drugs have been found to 
significantly affect clinical outcomes and delay 
disease progression. 
What are we doing wrong?  While several 
contributing factors may be responsible for the 
continuous failure of clinical trials, one common 
challenge that has continued to emerge and that all 
drug development scientists must consider is the 
timing of treatment and disease staging. Most 
clinical trial study designs in the past two decades 
have focused on administering treatment to patients 
with mild-to-moderate AD and measuring for 
improvement in symptoms or clinical outcomes as 
measured by various cognitive scales, an approach 
that worked well for acetylcholinesterase inhibitors 
and memantine.  However, these drugs targeted late 
stage processes contributing to overall cognitive 
symptoms with no effect on degenerative processes.  
It is now well known that the etiologic and 
neurodegenerative processes of AD start at least a 
decade prior to the appearance of symptoms.  At 
symptom start then, there is likely already 
significant irreversible neurodegeneration present. 
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Furthermore, the diagnosis of AD is not made until 
symptoms observably impair daily activities, at 
which point even more severe neurodegeneration is 
likely present.  Drug development scientists are 
increasingly recognizing that administering drug 
therapy even in mild-to-moderate disease may be 
too late to affect disease progression.  For instance, 
the EXPEDITION studies, which were the phase III 
trials of the monoclonal antibody solanezumab, an 
agent which was highly anticipated to be the most 
successful of all agents ever in development, failed 
to show benefit in the primary clinical outcome 
measure when administered in patients with mild to 
moderate AD.  However, when only early disease 
was evaluated (e.g mild AD), there was suggestion 
toward some benefit in patients with only middle 
disease.  As such, we are increasingly seeing study 
designs similar to that of the active vaccine CAD-
106, which is currently enrolling ApoE4 carriers 
who are cognitively and will measure the ability to 
delay diagnosis to MCI or AD dementia after 5 
years of treatment.  Studies of genetic forms of AD 
are easier to design, conduct, and analyze than 
studies of non-genetic forms of AD, as patient 
ascertainment through genotyping provides a 
reliable biomarker of likely AD development.  
However, genetic AD is much less common than 
non-genetic AD and design of clinical trials with 
early ascertainment of patients with non-genetic AD 
is absolutely necessary.  Early patient ascertainment 
with non-genetic forms of AD had previously been 
difficult, due to the lack of reliable biomarkers 
often leading to on-treatment groups containing 
people that would never go on to develop the 
disease anyways.  With the development and 
validation of the PET-ligand florbetapir, PET 
amyloid imaging can now be utilized as a 
biomarker in non-genetic forms of AD, allowing 
more accurate ascertainment of patients who would 
likely go on to develop AD for inclusion in clinical 
trials prior to them actually meeting clinical criteria 
for AD diagnosis. As such, agents such as 
solanezumab and bapenzumab and most recently 
the BACE inhibitor XYZ are enrolling or have 
announced plans to enroll patients in re-designed 
clinical trials that target patients with normal 
cognitive function who are deemed at risk for AD 
by PET amyloid imaging as inclusion criteria.  This 
recent trend in clinical trials shifts the participants 
towards earlier disease and younger ages, which in 
itself can potentially affect the interaction of the 
agent with intracellular mechanisms.    
AD drug development has undergone rapid 
growth in the past two decades.  Despite the lack of 
positive clinical trial outcomes, the lessons learned 
with each trial and each failure have brought us 
closer to a deeper understanding of the disease and 
the drugs we are using to combat the disease.  With 
an armamentarium that has been finely honed to 
optimize success, and the ability to now conduct 
appropriately designed clinical trials, we are at the 
dawn of a new era in the fight against this deadly 
disease that has plagued humanity for centuries. 
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